0001558370-24-014056.txt : 20241031 0001558370-24-014056.hdr.sgml : 20241031 20241031161536 ACCESSION NUMBER: 0001558370-24-014056 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 66 CONFORMED PERIOD OF REPORT: 20240930 FILED AS OF DATE: 20241031 DATE AS OF CHANGE: 20241031 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IRADIMED CORP CENTRAL INDEX KEY: 0001325618 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 731408526 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36534 FILM NUMBER: 241415425 BUSINESS ADDRESS: STREET 1: 1025 WILLA SPRINGS DR. CITY: WINTER SPRINGS STATE: FL ZIP: 32708 BUSINESS PHONE: 4076778022 MAIL ADDRESS: STREET 1: 1025 WILLA SPRINGS DR. CITY: WINTER SPRINGS STATE: FL ZIP: 32708 10-Q 1 irmd-20240930x10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended September 30, 2024

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No.: 001-36534

IRADIMED CORPORATION

(Exact name of Registrant as specified in its charter)


Delaware		73-1408526
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification Number)

1025 Willa Springs Drive Winter Springs, Florida		32708
(Address of principal executive offices)		(Zip Code)

(407) 677-8022

(Registrant’s telephone number, including area code)

N/A

(Former Name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class:	Trading Symbol	Name of each exchange on which registered:
Common stock, par value $0.0001	IRMD	NASDAQ Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company,” and “emerging growth company” as defined in Rule 12b-2 of the Exchange Act.


Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The registrant had 12,673,441 shares of common stock, par value $0.0001 per share, outstanding as of October 31, 2024.

Table of Contents

IRADIMED CORPORATION

Table of Contents

			Page
Cautionary Note Regarding Forward-Looking Statements			3

Part I	Financial Information		6

	Item 1	Financial Statements	6

		(a) Condensed Balance Sheets as of September 30, 2024 (Unaudited) and December 31, 2023 (Audited)	6

		(b) Condensed Statements of Operations for the three and nine months ended September 30, 2024 and 2023 (Unaudited)	7

		(c) Condensed Statements of Stockholders’ Equity for the three and nine months ended September 30, 2024 and 2023 (Unaudited)	8

		(d) Condensed Statements of Cash Flows for the nine months ended September 30, 2024 and 2023 (Unaudited)	9

		(e) Notes to Unaudited Condensed Financial Statements	10

	Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16

	Item 3	Quantitative and Qualitative Disclosures About Market Risk	23

	Item 4	Controls and Procedures	23

Part II	Other Information		24

	Item 1	Legal Proceedings	24

	Item 1A	Risk Factors	24

	Item 2	Unregistered Sale of Equity Securities and Use of Proceeds	24

	Item 3	Default Upon Senior Securities	24

	Item 4	Mine Safety Disclosures	24

	Item 5	Other Information	24

	Item 6	Exhibits	25

Signatures			26

Table of Contents

CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (this “Quarterly Report”) that are not historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. When used in this Quarterly Report the words “believe,” “anticipate,” “expect,” “may,” “will,” “assume,” “should,” “predict,” “could,” “would,” “intend,” “targets,” “estimates,” “projects,” “plans,” and “potential,” and other similar words and expressions of the future, are intended to identify such forward-looking statements, but other statements not based on historical information may also be considered forward-looking, including statements about the Company’s future financial and operating results and the Company’s plans, objectives, and intentions. All forward-looking statements are subject to risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to differ materially from any results, performance, or achievements expressed or implied by such forward-looking statements. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause the actual results to differ materially from the statements, including, but not limited to:

●

our ability to receive 510(k) clearance for our products and product candidates, complete inspections conducted by the U.S. Food & Drug Administration (“FDA”) or other regulatory bodies resulting in favorable outcomes, additional actions by or requests from the FDA, including a request to cease domestic distribution of products, or other regulatory bodies and unanticipated costs or delays associated with the resolution of these matters;

●

the timing and likelihood of regulatory approvals or clearances from the FDA or other regulatory bodies and regulatory actions on our product candidates and product marketing activities;

●

unexpected costs, expenses and diversion of management attention resulting from actions or requests posed to us by the FDA or other regulatory bodies;

●

our primary reliance on a limited number of products;

●

our ability to retain the continued service of our key professionals, including key management, marketing and scientific personnel, and to identify, hire and retain such additional qualified professionals;

●

our expectations regarding the sales and marketing of our products, product candidates and services;

●

our expectations regarding the integrity of our supply chain for our products;

●

the potential for adverse application of environmental, health and safety and other laws and regulations of any jurisdiction on our operations;

●

our expectations for market acceptance of our new products;

●

the potential for our marketed products to be withdrawn due to recalls, patient adverse events or deaths;

●

our ability to successfully prepare, file, prosecute, maintain, defend, including in cases of infringement, and enforce patent claims and other intellectual property rights on our products;

●

our ability to identify and pursue development of additional products;

●

the implementation of our business strategies;

●

the potential for exposure to product liability claims;

Table of Contents

●

our financial performance expectations and interpretations thereof by securities analysts and investors;

●

our ability to compete in the development and marketing of our products and product candidates with other companies in our industry;

●

difficulties or delays in the development, production, manufacturing and marketing of new or existing products and services, including difficulties or delays associated with obtaining requisite regulatory approvals or clearances associated with those activities;

●

changes in laws and regulations or in the interpretation or application of laws or regulations, as well as possible failures to comply with applicable laws or regulations as a result of possible misinterpretations or misapplications;

●

cost-containment efforts of our customers, purchasing groups, third-party payers and governmental organizations;

●

costs associated with protecting our trade secrets and enforcing our patent, copyright and trademark rights, and successful challenges to the validity of our patents, copyrights or trademarks;

●

actions of regulatory bodies and other government authorities, including the FDA and foreign counterparts, that could delay, limit or suspend product development, manufacturing or sales or result in recalls, seizures, consent decrees, injunctions and monetary sanctions;

●

costs or claims resulting from potential errors or defects in our manufacturing that may injure persons or damage property or operations, including costs from remediation efforts or recalls;

●

the results, consequences, effects or timing of any commercial disputes, patent infringement claims or other legal proceedings or any government investigations;

●

interruption in our ability to manufacture our products or an inability to obtain key components or raw materials or increased costs in such key components or raw materials;

●

uncertainties in our industry due to the effects of government-driven or mandated healthcare reform;

●

competitive pressures in the markets in which we operate;

●

potential negative impacts resulting from climate change or other environmental, social and governance and sustainability related matters;

●

the impact on our operations and financial results of any public health emergency and any related policies and actions by governments or other third parties;

●

breaches or failures of our or our vendors’ or customers’ information technology systems or products, including by cyber-attack, data leakage, unauthorized access or theft;

●

the loss of, or default by, one or more key customers or suppliers;

●

unfavorable changes to the terms of key customer or supplier relationships;

●

weakening of economic conditions, or the anticipation thereof, that could adversely affect the level of demand for our products;

Table of Contents

●

geopolitical risks, including from international conflicts and upcoming elections in the United States and other countries, which could, among other things, lead to increased market volatility; and

●

other risks detailed in our filings with the United States Securities and Exchange Commission (the “SEC”).

These forward-looking statements involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. Forward-looking statements should, therefore, be considered in light of various factors, including those set forth under “Part I, Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this Quarterly Report, and under “Part I, Item 1A. Risk Factors” and “Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “2023 Annual Report”) and those set forth from time to time in our other filings with the SEC. These documents are available through our website or through the SEC's Electronic Data Gathering and Analysis Retrieval system at http://www.sec.gov. In light of such risks and uncertainties, we caution you not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date of this Quarterly Report, or if earlier, as of the date they were made. We do not intend to, and disclaim any obligation to, update or revise any forward-looking statements unless required by securities law.

Unless expressly indicated or the context requires otherwise, references in this Quarterly Report to “IRADIMED,” the “Company,” “we,” “our,” and “us” refer to IRADIMED CORPORATION.

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Condensed Financial Statements

IRADIMED CORPORATION

CONDENSED BALANCE SHEETS


	September 30,		December 31,
	2024		2023
	(unaudited)		(audited)
ASSETS
Current assets:
Cash and cash equivalents	$	51,721,051	$	49,762,198
Accounts receivable, net of allowance for credit losses of $277,437 as of September 30, 2024, and $368,835 as of December 31, 2023		10,364,786		12,224,273
Inventory, net		11,251,549		12,821,194
Prepaid expenses and other current assets		948,841		1,193,447
Total current assets		74,286,227		76,001,112
Property and equipment, net		14,155,985		9,288,625
Intangible assets, net		2,891,657		2,519,053
Operating lease right-of-use asset		264,075		2,043,043
Deferred tax asset, net		2,464,604		2,122,816
Other assets		184,213		181,449
Total assets	$	94,246,761	$	92,156,098
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	1,400,544	$	1,857,091
Accrued payroll and benefits		3,284,226		2,775,103
Other accrued taxes		193,688		103,241
Warranty reserve		118,203		117,463
Deferred revenue		2,555,105		2,570,407
Dividend payable		—		7,975,997
Current portion of operating lease liabilities		261,244		427,963
Other current liabilities		250,000		250,000
Accrued income taxes		—		250,041
Total current liabilities		8,063,010		16,327,306
Deferred revenue, non-current		2,748,295		2,793,548
Operating lease liabilities, non-current		2,831		1,615,080
Total liabilities		10,814,136		20,735,934
Stockholders’ equity:
Common stock; $0.0001 par value per share; 31,500,000 shares authorized; 12,669,912 shares issued and outstanding as of September 30, 2024, and 12,660,313 shares issued and outstanding as of December 31, 2023		1,267		1,265
Additional paid-in capital		29,886,087		28,160,745
Retained earnings		53,545,271		43,258,154
Total stockholders' equity		83,432,625		71,420,164
Total liabilities and stockholders’ equity	$	94,246,761	$	92,156,098

See accompanying notes to unaudited condensed financial statements.

Table of Contents

IRADIMED CORPORATION

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)


	For the Three Months Ended				For the Nine Months Ended
	September 30,				September 30,
	2024		2023		2024		2023
Revenue	$	18,325,959	$	16,504,640	$	53,852,954	$	48,110,120
Cost of revenue		4,134,253		3,667,256		12,263,932		11,364,791
Gross profit		14,191,706		12,837,384		41,589,022		36,745,329
Operating expenses:
General and administrative		3,967,799		3,615,020		12,063,971		10,848,611
Sales and marketing		3,795,320		2,864,469		11,098,945		8,812,872
Research and development		639,467		452,555		2,261,596		2,208,221
Total operating expenses		8,402,586		6,932,044		25,424,512		21,869,704
Income from operations		5,789,120		5,905,340		16,164,510		14,875,625
Other income, net		629,201		503,192		1,766,572		1,180,988
Income before provision for income taxes		6,418,321		6,408,532		17,931,082		16,056,613
Provision for income tax expense		1,368,830		1,341,352		3,843,834		3,403,523
Net income	$	5,049,491	$	5,067,180	$	14,087,248	$	12,653,090
Net income per share:
Basic	$	0.40	$	0.40	$	1.11	$	1.00
Diluted	$	0.40	$	0.40	$	1.10	$	0.99
Weighted average shares outstanding:
Basic		12,669,741		12,602,581		12,665,743		12,597,250
Diluted		12,778,446		12,735,837		12,762,346		12,716,988

See accompanying notes to unaudited condensed financial statements.

Table of Contents

IRADIMED CORPORATION

CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)



				Additional
	Common Stock			Paid-in		Retained		Stockholders’
	Shares	Amount		Capital		Earnings		Equity
Balances, December 31, 2023	12,660,313	$	1,265	$	28,160,745	$	43,258,154	$	71,420,164
Net income	—		—		—		4,136,533		4,136,533
Stock-based compensation expense	—		—		628,640		—		628,640
Net share settlement of restricted stock units	3,872		1		(63,876)		—		(63,875)
Balances, March 31, 2024	12,664,185	$	1,266	$	28,725,509	$	47,394,687	$	76,121,462

Net income	—		—		—		4,901,224		4,901,224
Dividends paid $0.15 per share	—		—		—		(1,899,644)		(1,899,644)
Stock-based compensation expense	—		—		609,096		—		609,096
Net share settlement of restricted stock units	4,581		1		(63,946)		—		(63,945)
Exercise of stock options	335		—		3,296		—		3,296
Balances, June 30, 2024	12,669,101	$	1,267	$	29,273,955	$	50,396,267	$	79,671,489

Net income	—		—		—		5,049,491		5,049,491
Dividends paid $0.15 per share	—		—		—		(1,900,487)		(1,900,487)
Stock-based compensation expense	—		—		629,965		—		629,965
Net share settlement of restricted stock units	811		—		(17,833)		—		(17,833)
Balances, September 30, 2024	12,669,912	$	1,267	$	29,886,087	$	53,545,271	$	83,432,625



				Additional
	Common Stock			Paid-in		Retained		Stockholders’
	Shares	Amount		Capital		Earnings		Equity
Balances, December 31, 2022	12,591,004	$	1,259	$	26,407,446	$	47,264,282	$	73,672,987
Net income	—		—		—		3,406,070		3,406,070
Dividends paid $1.05 per share	—		—		—		(13,222,907)		(13,222,907)
Stock-based compensation expense	—		—		533,643		—		533,643
Net share settlement of restricted stock units	3,572		—		(49,878)		—		(49,878)
Balances, March 31, 2023	12,594,576	$	1,259	$	26,891,211	$	37,447,445	$	64,339,915

Net income	—		—		—		4,179,840		4,179,840
Stock-based compensation expense	—		—		568,453		—		568,453
Net share settlement of restricted stock units	5,965		1		(97,106)		—		(97,105)
Exercise of stock options	1,000		—		7,339		—		7,339
Balances, June 30, 2023	12,601,541	$	1,260	$	27,369,898	$	41,627,285	$	68,998,442

Net income	—		—		—		5,067,180		5,067,180
Stock-based compensation expense	—		—		533,749		—		533,749
Net share settlement of restricted stock units	1,310		—		(31,372)		—		(31,372)
Balances, September 30, 2023	12,602,851	$	1,260	$	27,872,275	$	46,694,465	$	74,568,000

See accompanying notes to unaudited condensed financial statements.

Table of Contents

IRADIMED CORPORATION

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)


	Nine Months Ended
	September 30,
	2024		2023
Operating activities:
Net income	$	14,087,248	$	12,653,090
Adjustments to reconcile net income to net cash provided by operating activities:
Allowance for credit losses		(91,398)		136,830
Provision for excess and obsolete inventory		202,140		219,928
Depreciation & amortization		622,790		559,805
Loss on disposal of property and equipment		3,872		12,535
Stock-based compensation		1,867,701		1,635,845
Deferred income taxes, net		(591,829)		(1,102,866)
Changes in operating assets and liabilities:
Accounts receivable		1,950,885		343,054
Inventory		1,278,208		(6,130,592)
Prepaid expenses and other current assets		244,606		(40,055)
Other assets		(2,764)		418,274
Accounts payable		(473,820)		519,648
Accrued payroll and benefits		509,123		(581,699)
Other accrued taxes		90,447		(18,696)
Warranty reserve		740		16,274
Deferred revenue		(60,555)		407,064
Other current liabilities		—		250,000
Prepaid income taxes		—		254,093
Net cash provided by operating activities		19,637,394		9,552,532
Investing activities:
Purchases of property and equipment		(5,214,859)		(6,908,607)
Capitalized intangible assets		(545,198)		(465,744)
Net cash used in investing activities		(5,760,057)		(7,374,351)
Financing activities:
Dividends paid		(11,776,128)		(13,222,907)
Proceeds from exercises of stock options		3,296		7,341
Taxes paid related to the net share settlement of equity awards		(145,652)		(178,355)
Net cash used in financing activities		(11,918,484)		(13,393,921)
Net increase/decrease in cash and cash equivalents		1,958,853		(11,215,740)
Cash and cash equivalents, beginning of period		49,762,198		57,960,864
Cash and cash equivalents, end of period	$	51,721,051	$	46,745,124
Supplemental disclosure of cash flow information:
Cash paid for income taxes	$	4,456,827	$	4,136,152
ROU asset recognized in exchange for new lease obligation	$	—	$	227,983
ROU asset and liability adjustment	$	1,486,093	$	—
Operating and short-term lease payments recorded within cash flow provided by operating activities	$	612,910	$	492,528

See accompanying notes to unaudited condensed financial statements.

Table of Contents

IRADIMED CORPORATION

Notes to Unaudited Condensed Financial Statements

1 — Basis of Presentation

The accompanying interim condensed financial statements of IRADIMED CORPORATION (“IRADIMED”, the “Company,” “we,” “our” and “us”) have been prepared pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally presented in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. The interim financial information is unaudited, but reflects all normal adjustments that are, in the opinion of management, necessary for the fair presentation of our financial position, results of operations and cash flows for the interim periods presented. Operating results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024, and other interim periods, or future years or periods.

The accompanying interim condensed financial statements should be read in conjunction with the financial statements and related footnotes to financial statements included in our 2023 Annual Report. The accounting policies followed in the preparation of these interim condensed financial statements, except as described in Note 1 herein, are consistent in all material respects with those described in Note 1 to the Financial Statements in the 2023 Annual Report.

We operate in one reportable segment, which is the development, manufacture and sale of Magnetic Resonance Imaging (“MRI”) compatible medical devices, related accessories, disposables and service for use primarily by hospitals and acute care facilities during MRI procedures.

Certain Significant Risks and Uncertainties

We market our products to end users in the United States and to third-party distributors internationally. Sales to end users in the United States are generally made on open credit terms. Management maintains an allowance for potential credit losses.

We have deposited our cash and cash equivalents with various financial institutions. Our cash and cash equivalents balances exceed federally insured limits regularly throughout the year. We have not incurred any losses related to these balances.

Our medical devices require clearance from the FDA and international regulatory agencies prior to commercialized sales. Our future products may not receive required approvals. If we were denied such approvals, or if such approvals were revoked or delayed or if we were unable to timely renew certain approvals for existing products, it would have a materially adverse impact on our business, results of operations and financial condition.

Certain key components of our products essential to their functionality are sole-sourced. Any disruption in the availability of these components would have a materially adverse impact on our business, results of operations and financial condition.

2 — Revenue Recognition

Disaggregation of Revenue

We disaggregate revenue from contracts with customers by geographic region and revenue type as we believe it best depicts the nature, amount, timing and uncertainty of our revenue and cash flow.

Table of Contents

Revenue information by geographic region is as follows:


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2024		2023		2024		2023

	(unaudited)				(unaudited)
United States	$	15,207,195	$	13,948,368	$	44,101,367	$	38,876,418
International		3,118,764		2,556,272		9,751,587		9,233,702
Total revenue	$	18,325,959	$	16,504,640	$	53,852,954	$	48,110,120

Revenue information by type is as follows:


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2024		2023		2024		2023

	(unaudited)				(unaudited)
Devices:
MRI Compatible Intravenous ("IV") Infusion Pump Systems	$	6,952,142	$	3,905,520	$	19,026,021	$	13,966,905
MRI Compatible Patient Vital Signs Monitoring Systems		5,926,028		7,738,549		17,837,910		18,564,085
Ferro Magnetic Detection Systems		128,505		138,760		744,607		619,539
Total Devices revenue		13,006,675		11,782,829		37,608,538		33,150,529
Disposables, services and other		4,735,066		4,213,666		14,604,879		13,464,278
Amortization of extended warranty agreements		584,218		508,145		1,639,537		1,495,313
Total revenue	$	18,325,959	$	16,504,640	$	53,852,954	$	48,110,120

Contract Liabilities

Our contract liabilities consist of:


	September 30,		December 31,
	2024		2023
	(unaudited)		(audited)
Advance payments from customers	$	216,097	$	508,956
Shipments in-transit		166,700		15,438
Extended warranty agreements		4,920,603		4,835,966
Total	$	5,303,400	$	5,360,360

Changes in the contract liabilities during the periods presented are as follows:


	Deferred
	Revenue
	(unaudited)
Contract liabilities, December 31, 2023	$	5,360,360
Increases due to cash received from customers		3,353,763
Decreases due to recognition of revenue		(3,410,723)
Contract liabilities, September 30, 2024	$	5,303,400


	Deferred
	Revenue
	(unaudited)
Contract liabilities, December 31, 2022	$	4,748,319
Increases due to cash received from customers		3,716,326
Decreases due to recognition of revenue		(3,309,262)
Contract liabilities, September 30, 2023	$	5,155,383

Table of Contents

Capitalized Contract Costs

Our capitalized contract costs totaled $164,898 and $162,134 as of September 30, 2024 and December 31, 2023, respectively, and are classified as other assets on the unaudited condensed balance sheets.

3 — Basic and Diluted Net Income per Share

Basic net income per share is based upon the weighted-average number of shares of Company common stock, par value $0.0001 per share (“common stock”), outstanding during the period. Diluted net income per share of common stock reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Stock options, restricted stock units and performance-based restricted stock units granted by us represent the only dilutive effect reflected in diluted weighted-average shares of common stock outstanding.

The following table presents the computation of basic and diluted net income per share of common stock:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023

	(unaudited)				(unaudited)
Net income	$	5,049,491	$	5,067,180	$	14,087,248	$	12,653,090
Weighted-average shares outstanding — Basic		12,669,741		12,602,581		12,665,743		12,597,250
Effect of dilutive securities:
Stock options		2,104		18,727		2,223		18,860
Restricted stock units		63,929		73,478		55,870		63,300
Performance-based restricted stock units		42,672		41,051		38,510		37,578
Weighted-average shares outstanding — Diluted		12,778,446		12,735,837		12,762,346		12,716,988
Basic net income per share	$	0.40	$	0.40	$	1.11	$	1.00
Diluted net income per share	$	0.40	$	0.40	$	1.10	$	0.99

Stock options and restricted stock units excluded from the calculation of diluted net income per share because the effect would have been anti-dilutive are as follows:


	Three Months Ended		Nine Months Ended
	September 30,		September 30,
	2024	2023	2024	2023

	(unaudited)		(unaudited)
Anti-dilutive stock options and restricted stock units	7	438	13	352

4 — Inventory, net

Inventory consists of:


	September 30,		December 31,
	2024		2023
	(unaudited)		(audited)
Raw materials	$	9,700,270	$	10,833,004
Work in process		703,363		501,191
Finished goods		1,470,786		1,907,729
Inventory before allowance for excess and obsolete		11,874,419		13,241,924
Allowance for excess and obsolete		(622,870)		(420,730)
Total	$	11,251,549	$	12,821,194

Table of Contents

5 — Property and Equipment, net

Property and equipment consist of:


	September 30,		December 31,
	2024		2023
	(unaudited)		(audited)
Land	$	6,253,790	$	6,253,790
Computer software and hardware		1,516,280		1,380,289
Furniture and fixtures		1,842,773		1,757,129
Leasehold improvements		270,486		270,486
Machinery and equipment		2,624,609		2,438,922
Construction in-process		6,108,204		1,257,844
		18,616,142		13,358,460
Accumulated depreciation		(4,460,157)		(4,069,835)
Total	$	14,155,985	$	9,288,625

Depreciation expense of property and equipment was $139,840 and $164,595 for the three months ended September 30, 2024 and 2023, respectively, and $450,194 and $484,094 for the nine months ended September 30, 2024 and 2023, respectively.

Property and equipment, net, information by geographic region is as follows:


	September 30,		December 31,
	2024		2023
	(unaudited)		(audited)
United States	$	13,746,389	$	8,950,580
International		409,596		338,045
Total property and equipment, net	$	14,155,985	$	9,288,625

Long-lived assets held outside of the United States consist principally of tooling and machinery and equipment, which are components of property and equipment, net.

6 — Intangible Assets, net

The following table summarizes the components of intangible asset balances:


	September 30,		December 31,
	2024		2023
	(unaudited)		(audited)
Patents — in use	$	321,874	$	321,874
Patents — fully amortized		70,164		70,164
Patents — in process		162,233		128,221
Internally developed software — in use		1,840,521		1,773,720
Internally developed software — in process		1,583,423		1,149,409
Trademarks		38,067		27,697
		4,016,282		3,471,085
Accumulated amortization		(1,124,625)		(952,032)
Total	$	2,891,657	$	2,519,053

Amortization expense of intangible assets was $57,731 and $25,236 for the three months ended September 30, 2024 and 2023, respectively, and $172,596 and $75,708 for the nine months ended September 30, 2024 and 2023, respectively.

Table of Contents

Expected annual amortization expense for the remaining portion of 2024 and the next five years related to intangible assets, excluding trademarks considered to have indefinite lives and in process intangible assets, is as follows:


Three months remaining ending December 31, 2024	$	59,518
2025	$	235,703
2026	$	223,987
2027	$	150,274
2028	$	147,672
Thereafter	$	290,780

7 — Fair Value Measurements

The fair values of cash equivalents, accounts receivables net, and accounts payable approximate their carrying amounts due to their short duration.

As of September 30, 2024, we did not have any assets or liabilities subject to recurring fair value measurements.

8 — Stock-Based Compensation

Stock-based compensation was recognized as follows in the unaudited Condensed Statements of Operations:


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2024		2023		2024		2023

	(unaudited)				(unaudited)
Cost of revenue	$	62,359	$	63,119	$	178,713	$	187,292
General and administrative		381,339		290,370		1,139,316		871,100
Sales and marketing		135,358		129,340		393,649		435,707
Research and development		50,908		50,919		156,023		141,746
Total	$	629,964	$	533,748	$	1,867,701	$	1,635,845

As of September 30, 2024, we had (i) $2,875,176 of unrecognized compensation cost related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of 2.14 years and (ii) $866,155 of unrecognized compensation cost related to unvested performance-based restricted stock units, which is expected to be recognized over a weighted-average period of 1.82 years.

The following table presents a summary of our equity award activity for the nine months ended September 30, 2024 (shares):


	Nine Months Ended
	September 30, 2024
			Performance
			Based
	Stock	Restricted	Restricted
	Options	Stock Units	Stock Units
Outstanding beginning of period	3,010	141,327	36,792
Awards granted	—	5,353	—
Awards exercised/vested	(335)	(12,601)	—
Awards canceled/ forfeited	—	(2,848)	—
Outstanding end of period	2,675	131,231	36,792

Table of Contents

9 — Income Taxes

For the three and nine months ended September 30, 2024, we recorded a provision for income tax expense of $1,368,830 and $3,843,834, respectively. For the three and nine months ended September 30, 2024, our effective tax rate was 21.3% and 21.4%, respectively, and differed from the U.S. Federal statutory rate primarily due to U.S. state income tax expense, partially offset by benefits from research and development tax credits.

For the three and nine months ended September 30, 2023, we recorded a provision for income tax expense of $1,341,352 and $3,403,523, respectively. For the three and nine months ended September 30, 2023, our effective tax rate was 20.9% and 21.2%, respectively, and differed from the U.S. Federal statutory rate primarily due to U.S. state income tax expense, partially offset by benefits from research and development tax credits.

On July 31, 2024, the Company received notice of examination from the U.S. Internal Revenue Service for the tax year ended December 31, 2021. We are currently complying with the taxing authority and believe our tax position for the year under review was appropriate and have not accounted for any proposed adjustments at this time. The Company remains subject to income tax examinations for our United States Federal and certain U.S. state income taxes for 2019 and subsequent years.

10 — Leases

We have entered into operating lease contracts for our manufacturing plant, office space, and various office equipment with two material lease contracts outstanding.

In January 2014, we entered into a non-cancelable operating lease, commencing on July 1, 2014, for our manufacturing and headquarters facility in Winter Springs, Florida owned by Susi, LLC, an entity controlled by our President, Chief Executive Officer, and Chairman of the Board, Roger Susi. Pursuant to the terms of our lease for this property, the monthly base rent is $34,133, adjusted annually for changes in the consumer price index. The Company paid Susi, LLC $160,266 and $127,817 for the three months ended September 30, 2024 and 2023, respectively. For the nine months ended September 30, 2024 and 2023, the Company paid Susi, LLC $479,561 and $386,958, respectively. On May 31, 2019, the expiration date of the initial lease term, and pursuant to the terms of the lease contract, we renewed the lease for an additional five years, which was set to expire on May 31, 2024.

On May 29, 2024, the Company entered into a lease amendment (the “Lease Amendment”) with Susi, LLC under which it did not exercise the second five-year option because of the Company’s continued construction of a new corporate office and manufacturing facility in Orange County, Florida. Pursuant to the terms of the Lease Amendment, the monthly base rent is $34,133, adjusted annually for changes in the consumer price index, and the Lease Amendment has an expiration date of May 31, 2025, and includes an option to renew on a month-to-month basis for up to six months thereafter. The impact of the Lease Amendment to the Right-of-Use (“ROU”) asset valuation is a reduction in the ROU lease liability and ROU assets in the amount of $1.48 million. It has no impact to the statements of operations or cash flow. This Lease Amendment does not contain any residual value guarantee or material restrictive covenants.

In February 2023, we entered into two, two-year, non-cancelable operating leases with non-related parties for additional office space in Winter Springs, Florida. Pursuant to the lease terms, the total monthly base rent is $10,055. For the three months ended September 30, 2024 and 2023, the Company paid $30,165 and $30,165, respectively. For the nine months ended September 30, 2024 and 2023, the Company paid $90,495 and $83,140, respectively. Under the terms of the leases, we are responsible for insurance and maintenance expenses. Pursuant to the contract terms, the leases will expire in February 2025 and do not contain any residual value guarantee or material restrictive covenants.

Table of Contents

Operating lease cost recognized in the unaudited Condensed Statements of Operations is as follows:


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2024		2023		2024		2023

	(unaudited)				(unaudited)
Cost of revenue	$	59,124	$	58,086	$	176,810	$	174,258
General and administrative		88,666		87,639		265,442		255,562
Sales and marketing		3,309		3,251		9,895		9,752
Research and development		9,167		9,006		27,414		27,019
Total	$	160,266	$	157,982	$	479,561	$	466,591

Lease costs for short-term leases were immaterial for the three and nine months ended September 30, 2024 and 2023.

Maturity of our operating lease liability as of September 30, 2024, is as follows:


Three months remaining ending December 31, 2024	$	152,972
Thereafter		173,514
Total lease payments		326,486
Imputed interest		(62,411)
Present value of lease liability	$	264,075

11 — Commitments and Contingencies

Purchase commitments. We had various purchase orders for goods or services totaling $6,921,468 and $8,217,571 as of September 30, 2024 and December 31, 2023, respectively. Amounts recognized in our balance sheet related to these purchase orders were immaterial.

Legal matters. We may, from time to time, become a party to various legal proceedings or claims that arise in the ordinary course of business. As of September 30, 2024 and December 31, 2023, we had an accrued total balance of approximately $250,000 in each period related to various matters.

12 — Subsequent Events

On October 30, 2024, the Company’s Board of Directors declared a regular quarterly cash dividend of $0.15 per share on the Company's outstanding common stock. The payment will be made to stockholders on November 25, 2024, to stockholders of record at the close of business on November 15, 2024.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with our unaudited condensed financial statements and the related notes to those statements included in this Quarterly Report, the discussion of certain risks and uncertainties contained in “Part I, Item 1A, Risk Factors” of this Quarterly Report, the discussion under “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Part I, Item 1. Business” included in the 2023 Annual Report and the “Cautionary Statements Regarding Forward-Looking Statements” section at the beginning of this Quarterly Report.

Table of Contents

Our Business

We develop, manufacture, market and distribute MRI compatible medical devices and accessories, disposables and services relating to them.

We are a leader in the development of innovative MRI compatible medical devices. We are the only known provider of a non-magnetic IV infusion pump system that is specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components, which can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated to remain immobile during an MRI scan.

Each IV infusion pump system consists of an MRidium® MRI compatible IV infusion pump, non-magnetic mobile stand, proprietary disposable IV tubing sets and many of these systems contain additional optional upgrade accessories.

Our 3880 MRI compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The IRADIMED 3880 has a compact, lightweight design allowing it to travel with the patient from their critical care unit to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the IRADIMED 3880 include: wireless Electrocardiogram (ECG) with dynamic gradient filtering; wireless blood oxygen saturation monitoring (SpO2) using Masimo® algorithms; non-magnetic respiratory carbon dioxide (CO2); invasive and non-invasive blood pressure; patient temperature; and optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The IRADIMED 3880 MRI compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians.

We generate revenue from the sale of MRI compatible medical devices and accessories, extended warranty agreements, services related to maintaining our products and the sale of disposable products used with our devices. The principal customers for our MRI compatible products include hospitals and acute care facilities, both in the United States and internationally. As of September 30, 2024, our direct U.S. sales force consisted of 27 field sales representatives, 4 regional sales directors and supplemented by 8 clinical application specialists. Internationally, we have distribution agreements with independent distributors selling our products.

Selling cycles for our devices have varied widely and have historically ranged between three and six months in duration. We also enter into agreements with integrated delivery networks (“IDNs”) and healthcare supply contracting companies, which are commonly referred to as group purchasing organizations (“GPOs”) in the U.S., which enable us to sell and distribute our products to their member hospitals. GPOs negotiate volume purchase prices for hospitals, group practices, and other clinics that are members of a GPO. Under our GPO agreements, we are required to pay the GPOs a fee of three percent of the sales of our products to members of the GPO. Sales to participating IDNs do not have an associated fee.

Financial Highlights

For the quarter ended September 30, 2024, our revenue increased by $1.8 million, or 11.0% to $18.3 million, compared to $16.5 million for the quarter ended September 30, 2023. Income before the provision for income taxes was $6.4 million for the quarter ended September 30, 2024, compared to $6.4 million for the quarter ended

Table of Contents

September 30, 2023. Net income remained consistent at $5.0 million, or $0.40 per diluted share in the quarter ended September 30, 2024, compared to the quarter ended September 30, 2023.

For the remainder of 2024, we expect higher revenue when compared to the same period in 2023 primarily due to higher sales of our medical devices, related accessories, disposables, and services. We also expect higher operating expenses compared to the same period in 2023 primarily due to higher sales and marketing, regulatory, and general and administrative expenses.

Critical Accounting Estimates

The discussion and analysis of our financial condition and results of operations are based on our unaudited condensed financial statements, which we have prepared in accordance with GAAP. The preparation of these unaudited condensed financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements as well as the reported revenue and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

We believe that the estimates, assumptions and judgments involved in the accounting policies described in “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our 2023 Annual Report have the greatest potential impact on our financial statements, so we consider them to

be our critical accounting policies and estimates. As of September 30, 2024, there were no material changes to the information provided regarding recent accounting pronouncements in Note 1 to the Financial Statements in the 2023 Annual Report.

Results of Operations

The following table sets forth selected statements of operations data as a percentage of total revenue for the periods indicated. Our historical operating results are not necessarily indicative of the results for any future period.


	Percent of Revenue				Percent of Revenue
	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2024		2023		2024		2023
	(unaudited)				(unaudited)
Revenue	100.0	%	100.0	%	100.0	%	100.0	%
Cost of revenue	22.6		22.2		22.8		23.6
Gross profit	77.4		77.8		77.2		76.4
Operating expenses:
General and administrative	21.7		21.9		22.4		22.5
Sales and marketing	20.7		17.4		20.6		18.3
Research and development	3.5		2.7		4.2		4.6
Total operating expenses	45.9		42.0		47.2		45.4
Income from operations	31.6		35.8		30.0		30.9
Other income, net	3.4		3.0		3.3		2.5
Income before provision for income taxes	35.0		38.8		33.3		33.4
Provision for income tax expense	7.5		8.1		7.1		7.1
Net income	27.5	%	30.7	%	26.2	%	26.3	%

Table of Contents

Comparison of the Three Months Ended and Nine Months Ended September 30, 2024 and 2023

Revenue by Geographic Region


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2024		2023		2024		2023

	(unaudited)				(unaudited)
United States	$	15,207,195	$	13,948,368	$	44,101,367	$	38,876,418
International		3,118,764		2,556,272		9,751,587		9,233,702
Total revenue	$	18,325,959	$	16,504,640	$	53,852,954	$	48,110,120

Revenue by Type


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2024		2023		2024		2023

	(unaudited)				(unaudited)
Devices:
MRI Compatible IV Infusion Pump Systems	$	6,952,142	$	3,905,520	$	19,026,021	$	13,966,905
MRI Compatible Patient Vital Signs Monitoring Systems		5,926,028		7,738,549		17,837,910		18,564,085
Ferro Magnetic Detection Systems		128,505		138,760		744,607		619,539
Total Devices revenue		13,006,675		11,782,829		37,608,538		33,150,529
Disposables, services and other		4,735,066		4,213,666		14,604,879		13,464,278
Amortization of extended warranty agreements		584,218		508,145		1,639,537		1,495,313
Total revenue	$	18,325,959	$	16,504,640	$	53,852,954	$	48,110,120

For the three months ended September 30, 2024, revenue increased by $1.8 million, or 11.0%, to $18.3 million from $16.5 million for the same period in 2023. This is attributed to continued demand for our IV Infusion Pump System, Disposables and extended warranty revenue.

Revenue from sales in the U.S. increased by $1.3 million, or 9.4%, to $15.2 million for the three months ended September 30, 2024, from $13.9 million for the same period in 2023. Revenue from sales internationally increased by $0.5 million, or 19.2%, for the three months ended September 30, 2024 to $3.1 million, from $2.6 million for the same period in 2023. Domestic sales accounted for 82.9% of revenue for the three months ended September 30, 2024, compared to 84.2% for the same period in 2023.

Revenue from sales of devices increased by $1.2 million, or 10.4%, to $13.0 million for the three months ended September 30, 2024, from $11.8 million for the same period in 2023.

Revenue from sales of our disposables, service and other increased by $0.5 million, or 11.9%, to $4.7 million for the three months ended September 30, 2024, from $4.2 million for the same period in 2023. Revenue from the amortization of extended warranty agreements increased by $0.1 million, or 15.0%, to $0.6 million for the three months ended September 30, 2024, from $0.5 million for the three months ended September 30, 2023.

For the nine months ended September 30, 2024, revenue increased by $5.7 million, or 11.9%, to $53.9 million from $48.1 million for the same period in 2023. This is attributed to the increase in our IV Infusion Pump System, Ferro Magnetic Detection System, Disposables, and extended warranty revenue.

Revenue from sales in the U.S. increased by $5.2 million, or 13.4%, to $44.1 million for the nine months ended September 30, 2024, from $38.9 million for the same period 2023. Revenue from sales internationally increased $0.6

Table of Contents

million, or 6.5%, to $9.8 million for the nine months ended September 30, 2024, from $9.2 million for the nine months ended September 30, 2023. Domestic sales accounted for 81.9% of revenue for the nine months ended September 30, 2024, compared to 80.9% for the nine months ended September 30, 2023.

Revenue from sales of devices increased by $4.4 million, or 13.4%, to $37.6 million for the nine months ended September 30, 2024, from $33.2 million for the same period in 2023.

Revenue from sales of our disposables, service and other increased by $1.1 million, or 8.5%, to $14.6 million for the nine months ended September 30, 2024, from $13.5 million for the same period in 2023. Revenue from the amortization of extended warranty agreements increased by $0.1 million, or 9.6%, to $1.6 million for the nine months ended September 30, 2024, from $1.5 million for the nine months ended September 30, 2023.

Cost of Revenue and Gross Profit


	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2024			2023			2024			2023

	(unaudited)						(unaudited)
Revenue	$	18,325,959		$	16,504,640		$	53,852,954		$	48,110,120
Cost of revenue		4,134,253			3,667,256			12,263,932			11,364,791
Gross profit	$	14,191,706		$	12,837,384		$	41,589,022		$	36,745,329
Gross profit percentage		77.4	%		77.8	%		77.2	%		76.4	%

For the three months ended September 30, 2024 our cost of revenue increased by $0.4 million, or 12.3%, to $4.1 million from $3.7 million for the same period in 2023. For the three months ended September 30, 2024, our gross profit increased by $1.4 million, or 10.5%, to $14.2 million from $12.8 million for the same period in 2023. Gross profit margin was 77.4% for the three months ended September 30, 2024, compared to 77.8% for the same period in 2023. The decrease in gross profit margin is primarily due to a favorable inventory adjustment in prior year and current quarter geographic sales mix.

For the nine months ended September 30, 2024, cost of revenue increased by $0.9 million, or 7.9%, to $12.3 million from $11.4 million for the same period in 2023. Gross profit increased by $4.9 million, or 13.2%, to $41.6 million for the nine months ended September 30, 2024 from $36.7 million for the same period in 2023. Gross profit margin was 77.2% for the nine months ended September 30, 2024, compared to 76.4% for the same period in 2023. The increase in gross profit margin is primarily due to decreased raw material costs, favorable geographic sales mix, and overhead spent as a percentage of revenue.

Operating Expenses


	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2024			2023			2024			2023
	(unaudited)						(unaudited)
General and administrative	$	3,967,799		$	3,615,020		$	12,063,971		$	10,848,611
Percentage of revenue		21.7	%		21.9	%		22.4	%		22.5	%
Sales and marketing	$	3,795,320		$	2,864,469		$	11,098,945		$	8,812,872
Percentage of revenue		20.7	%		17.4	%		20.6	%		18.3	%
Research and development	$	639,467		$	452,555		$	2,261,596		$	2,208,221
Percentage of revenue		3.5	%		2.7	%		4.2	%		4.6	%

General and Administrative

For the three months ended September 30, 2024, general and administrative expense increased by $0.4 million, or 11.1%, to $4.0 million from $3.6 million for the same period in 2023. This increase is primarily due to higher legal and professional expenses, software maintenance, and increased payroll and benefit expenses.

Table of Contents

For the nine months ended September 30, 2024, general and administrative expense increased by $1.3 million, or 12.0%, to $12.1 million from $10.8 million for the same period last year. This increase is primarily due to higher legal and professional expenses, regulatory consulting, and payroll and benefits expenses.

Sales and Marketing

For the three months ended September 30, 2024, sales and marketing expense increased by $0.9 million, or 31.0%, to $3.8 million from $2.9 million for the same period in 2023. This increase is primarily due to higher sales commissions, sales activities expenses, and payroll and benefits expenses.

For the nine months ended September 30, 2024, sales and marketing expense increased by $2.3 million, or 26.1%, to $11.1 million from $8.8 million for the same period last year. This increase is primarily due to higher sales commissions, sales activities expenses, and payroll and benefits expenses.

Research and Development

For the three months ended September 30, 2024, research and development expense increased by $0.1 million, or 20.0%, to $0.6 million from $0.5 million for the same period in 2023. This is primarily due to us no longer allocating recently approved product parts related to the next generation pump to research and development, offset by increased payroll and benefit expenses. These approved parts are now included in raw material inventory.

For the nine months ended September 30, 2024, research and development expense increased by $0.1 million, or 4.5%, to $2.3 million from $2.2 million for the same period last year. This is primarily due to higher payroll and benefits expenses as well as software maintenance, and consulting expenses related to the next generation pump.

Other Income, Net

Other income, net consists of interest income, foreign currency gains and losses, and other miscellaneous income. For the three months ended September 30, 2024, other income, net increased by $0.1 million, to $0.6 million from $0.5 million for the same period in 2023. This increase is due to higher interest rates earned by money market fund investments that comprise a significant portion of our cash balances.

For the nine months ended September 30, 2024 and 2023, we reported other income, net, of $1.8 million and $1.2 million, respectively. The change is primarily due to higher interest rates earned by money market fund investments.

Income Taxes

For the three and nine months ended September 30, 2024, we recorded a provision for income tax expense of $1,368,830 and $3,843,834, respectively. Our effective tax rate was 21.3% and 21.4% for the three and nine months ended September 30, 2024, respectively, and differed from the U.S. Federal statutory rate primarily due to U.S. state income tax expense, partially offset by research and development tax credits.

For the three and nine months ended September 30, 2023, we recorded a provision for income tax expense of $1,341,352 and $3,403,523, respectively. Our effective tax rate was 20.9% and 21.2%, respectively, and differed from the U.S. Federal statutory rate primarily due to U.S. Federal income tax expense partially offset by research and development tax credits.

Table of Contents

Liquidity and Capital Resources

Our principal sources of liquidity have historically been our cash and cash equivalents balances, cash flow from operations and access to the financial markets. Our principal uses of cash are operating expenses, working capital requirements, capital expenditures and dividend payments, if any.

As of September 30, 2024, we had cash and cash equivalents of $51.7 million, stockholders’ equity of $83.4 million, and working capital of $66.2 million. As of December 31, 2023, we had cash and cash equivalents of $49.8 million, stockholders’ equity of $71.4 million, and working capital of $59.7 million.

On April 3, 2024, the Company filed a shelf registration statement on Form S-3 (the “2024 Shelf”), which was declared effective by the SEC on May 8, 2024. The 2024 Shelf covers the offering, issuance and sale by the Company of up to an aggregate of $75.0 million of its common stock. As of September 30, 2024, all $75.0 million remained available under the 2024 Shelf.

We believe that our current cash, and any cash generated from operations will be sufficient to meet our ongoing operating requirements for at least the next 12 months and into the foreseeable future. We do not anticipate requiring additional capital; however, if required or desirable, we may seek to obtain a credit facility, raise debt, or issue additional equity in private or public markets.


	Nine Months Ended
	September 30,
	2024		2023

	(unaudited)
Net cash provided by operating activities	$	19,637,394	$	9,552,532
Net cash used in investing activities		(5,760,057)		(7,374,351)
Net cash used in financing activities		(11,918,484)		(13,393,921)

Cash provided by operating activities increased by $10.0 million, to $19.6 million for the nine months ended September 30, 2024, compared to $9.6 million for the same period in 2023. During the nine months ended September 30, 2024, cash provided by operations was positively impacted by net income, lower inventory purchases, and reduced accounts receivable and negatively impacted by higher cash outflows related to accounts payable.

Cash used in investing activities decreased by $1.6 million, to $5.8 million for the nine months ended September 30, 2024, compared to $7.4 million for the same period in 2023. For the nine months ended September 30, 2023, we acquired land for $6.2 million in cash to be used for future office, assembly, warehouse, and shipping space to accommodate our increased operations and anticipated growth. The majority of our 2024 spend in investing activities is attributed to construction costs of our new facility on the aforementioned land.

Cash used in financing activities decreased by $1.5 million, to $11.9 million for the nine months ended September 30, 2024, compared to approximately $13.4 million for the same period in 2023. In both periods, the Company paid special dividends to our stockholders; and in the 2024 period, we commenced a regular quarterly dividend policy, subject to the sole discretion of the Company’s Board of Directors and applicable law.

We market our products to end users in the U.S. and to distributors internationally. Sales to end users in the U.S. are generally made on open credit terms. Management maintains an allowance for potential credit losses.

Our current manufacturing and headquarters facility has been leased from Susi, LLC, an entity controlled by our President, Chief Executive Officer, and Chairman of the Board, Roger Susi. Pursuant to the terms of the Lease Amendment, the monthly base rent is $34,133, adjusted annually for changes in the consumer price index.

Table of Contents

Off-Balance Sheet Arrangements

As of September 30, 2024 and December 31, 2023, we did not have any off-balance sheet arrangements, as such term is defined under Item 303 of Regulation S-K, that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Contractual Obligations

There have been no material changes outside the ordinary course of business to our contractual obligations and commercial commitments since December 31, 2023.

Recent Accounting Pronouncements

As of September 30, 2024, there were no material changes to the information provided regarding recent accounting pronouncements in Note 1 to the Financial Statements in the 2023 Annual Report.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

There have been no material changes in our market risks from those disclosed in “Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk” of the 2023 Annual Report.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)) of the Exchange Act are designed to ensure that: (1) information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms; and (2) such information is accumulated and communicated to management, including the principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosures. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives.

Our management, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2024. Our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures as of September 30, 2024 were effective.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report that has materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

We may from time to time become party to various legal proceedings or claims that arise in the ordinary course of business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. We accrue liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. We do not believe that any such matters, individually or in the aggregate, will have a material adverse effect on our business, financial condition, results of operations or cash flows.

Item 1A. Risk Factors

In addition to the other information set forth in this Quarterly Report, you should carefully consider the risks discussed in our 2023 Annual Report and those set forth from time to time in our other filings with the SEC. There have been no material changes in our risk factors from those described in our 2023 Annual Report. The risks described in such report are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition, or future results.

Item 2. Unregistered Sale of Equity Securities and Use of Proceeds

None.

Item 3. Default Upon Senior Securities

Not Applicable.

Item 4. Mine Safety Disclosures.

Not Applicable.

Item 5. Other Information

Rule 10b5-1 Trading Arrangement Changes

None of the Company's directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the quarterly period ended September 30, 2024.

Table of Contents

Item 6. Exhibits

Exhibit Number		Description of Document
31.1		Certification of Chief Executive Officer pursuant to Exchange Act Rule, 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification of Chief Financial Officer pursuant to Exchange Act Rule, 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*		Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		Inline XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document
104		Inline XBRL for the cover page of this Quarterly Report , included as part of this Exhibit 101 inline XBRL Document set

This exhibit shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filings.

Table of Contents

IRADIMED CORPORATION

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	IRADIMED CORPORATION

Dated: October 31, 2024	/s/ Roger Susi
	By:	Roger Susi
	Its:	Chief Executive Officer and President
		(Principal Executive Officer and Authorized Officer)

	/s/ John Glenn
	By:	John Glenn
	Its:	Chief Financial Officer
		(Principal Financial and Accounting Officer)

EX-31.1 2 irmd-20240930xex31d1.htm EX-31.1

Exhibit 31.1

Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Roger Susi, hereby certify that:

1.	I have reviewed this quarterly report on Form 10-Q of IRADIMED CORPORATION;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: October 31, 2024

/s/ Roger Susi
By: Roger Susi
Chief Executive Officer and President
(Principal Executive Officer)

EX-31.2 3 irmd-20240930xex31d2.htm EX-31.2

Exhibit 31.2

Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, John Glenn, hereby certify that:

1.	I have reviewed this quarterly report on Form 10-Q of IRADIMED CORPORATION;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)

(d)

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 31, 2024

/s/ John Glenn
By: John Glenn
Chief Financial Officer
(Principal Financial and Accounting Officer)

EX-32.2 4 irmd-20240930xex32d2.htm EX-32.2

Exhibit 32.1

Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the quarterly report of IRADIMED CORPORATION (the “Company”) on Form 10-Q for the quarter ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

3
/s/ Roger Susi
By: Roger Susi
Chief Executive Officer and President
(Principal Executive Officer)
October 31, 2024

/s/ John Glenn
By: John Glenn
Chief Financial Officer
(Principal Financial and Accounting Officer)
October 31, 2024

EX-101.SCH 5 irmd-20240930.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 995200100 - Statement - CONDENSED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 995200200 - Statement - CONDENSED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 995200400 - Statement - CONDENSED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 99940202 - Disclosure - Revenue Recognition - Information by type (Details) link:presentationLink link:calculationLink link:definitionLink 99940203 - Disclosure - Revenue Recognition - Contract liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 99940401 - Disclosure - Inventory, net (Details) link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - Property and Equipment, net (Details) link:presentationLink link:calculationLink link:definitionLink 99940601 - Disclosure - Intangible Assets, net (Details) link:presentationLink link:calculationLink link:definitionLink 99941003 - Disclosure - Leases - Maturity of operating lease liability (Details) link:presentationLink link:calculationLink link:definitionLink 41203 - Disclosure - Leases - Maturity of lease liabilities (Details) Calc 2 link:presentationLink link:calculationLink link:definitionLink 995200300 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 99930803 - Disclosure - Stock Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 99940101 - Disclosure - Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 99940201 - Disclosure - Revenue Recognition - Information by geographic region (Details) link:presentationLink link:calculationLink link:definitionLink 99940502 - Disclosure - Property and Equipment, net - geographic region (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - Stock-Based Compensation - Stock-based compensation expense (Details) link:presentationLink link:calculationLink link:definitionLink 99940802 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 99940803 - Disclosure - Stock-Based Compensation - Performance-Based Restricted Stock Units - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99940804 - Disclosure - Stock-Based Compensation - Stock Options and Restricted Stock Units Activity (Details) link:presentationLink link:calculationLink link:definitionLink 99941001 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 99941002 - Disclosure - Leases - Operating lease cost (Details) link:presentationLink link:calculationLink link:definitionLink 99941101 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 99941201 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 995200090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 995200105 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995200305 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - Basic and Diluted Net Income per Share link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - Inventory, net link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - Property and Equipment, net link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - Intangible Assets, net link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995210901 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995211001 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 995211101 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995211201 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 99920102 - Disclosure - Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 99930203 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 99930303 - Disclosure - Basic and Diluted Net Income per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 99930403 - Disclosure - Inventory, net (Tables) link:presentationLink link:calculationLink link:definitionLink 99930503 - Disclosure - Property and Equipment, net (Tables) link:presentationLink link:calculationLink link:definitionLink 99930603 - Disclosure - Intangible Assets, net (Tables) link:presentationLink link:calculationLink link:definitionLink 99931003 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 99940204 - Disclosure - Revenue Recognition- Capitalized contract costs (Details) link:presentationLink link:calculationLink link:definitionLink 99940301 - Disclosure - Basic and diluted net income per share (Details) link:presentationLink link:calculationLink link:definitionLink 99940901 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 irmd-20240930_cal.xml EX-101.CAL EX-101.DEF 7 irmd-20240930_def.xml EX-101.DEF EX-101.LAB 8 irmd-20240930_lab.xml EX-101.LAB Document and Entity Information Document Type Document Quarterly Report Document Period End Date Document Transition Report Securities Act File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag CONDENSED BALANCE SHEETS Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Accounts Receivable, after Allowance for Credit Loss, Current Accounts receivable, net of allowance for credit losses of $277,437 as of September 30, 2024, and $368,835 as of December 31, 2023 Inventory, Net Inventory, net Total Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Total Total property and equipment, net Finite-Lived Intangible Assets, Net Intangible assets, net Total Operating Lease, Right-of-Use Asset Operating lease right-of-use asset Deferred Income Tax Assets, Net Deferred tax asset, net Other Assets, Noncurrent Other assets Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Employee-related Liabilities, Current Accrued payroll and benefits Accrual for Taxes Other than Income Taxes, Current Other accrued taxes Product Warranty Accrual, Current Warranty reserve Contract with Customer, Liability, Current Deferred revenue Dividends Payable, Current Dividend payable Dividends declared not yet paid Operating Lease, Liability, Current Current portion of operating lease liabilities Other Liabilities, Current Other current liabilities Accrued Income Taxes, Current Accrued income taxes Liabilities, Current Total current liabilities Contract with Customer, Liability, Noncurrent Deferred revenue, non-current Operating Lease, Liability, Noncurrent Operating lease liabilities, non-current Liabilities Total liabilities Equity, Attributable to Parent [Abstract] Stockholders' equity: Common Stock, Value, Issued Common stock; $0.0001 par value per share; 31,500,000 shares authorized; 12,669,912 shares issued and outstanding as of September 30, 2024, and 12,660,313 shares issued and outstanding as of December 31, 2023 Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Retained earnings Equity, Attributable to Parent Ending balances Beginning balances Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Accounts Receivable, Allowance for Credit Loss, Current Allowance for credit losses Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding CONDENSED STATEMENTS OF OPERATIONS Revenues Revenue Cost of Revenue Cost of revenue Gross Profit Gross profit Operating Expenses [Abstract] Operating expenses: General and Administrative Expense General and administrative Selling and Marketing Expense Sales and marketing Research and Development Expense Research and development Operating Expenses Total operating expenses Operating Income (Loss) Income from operations Nonoperating Income (Expense) Other income, net Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income before provision for income taxes Income Tax Expense (Benefit) Provision for income tax expense Net income Earnings Per Share, Basic [Abstract] Net income per share: Earnings Per Share, Basic Basic net income per share (in dollars per share) Basic (in dollars per share) Earnings Per Share, Diluted Diluted net income per share (in dollars per share) Diluted (in dollars per share) Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted average shares outstanding: Weighted Average Number of Shares Outstanding, Basic Weighted-average shares outstanding - Basic Basic (in shares) Weighted Average Number of Shares Outstanding, Diluted Weighted-average shares outstanding - Diluted (in shares) Diluted (in shares) CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY Statement [Table] Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional Paid-In Capital Retained Earnings [Member] Retained Earnings Statement [Line Items] Statement Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity Shares, Outstanding Ending balances (in shares) Beginning balances (in shares) Dividends, Common Stock, Cash Dividends paid APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense Restricted Stock, Value, Shares Issued Net of Tax Withholdings Net share settlement of restricted stock units Restricted Stock, Shares Issued Net of Shares for Tax Withholdings Net share settlement of restricted stock units (in shares) Stock Issued During Period, Value, Stock Options Exercised Exercise of stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Awards exercised/vested (in shares) Exercise of stock options (in shares) This information represents dividend paid per share in amount. Dividends Paid Amount Per Share CONDENSED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities [Abstract] Operating activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net income Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash provided by operating activities: Accounts Receivable, Credit Loss Expense (Reversal) Allowance for credit losses Inventory Write-down Provision for excess and obsolete inventory Depreciation, Depletion and Amortization Depreciation & amortization Gain (Loss) on Disposition of Property Plant Equipment Loss on disposal of property and equipment Share-Based Payment Arrangement, Noncash Expense Stock-based compensation Increase (Decrease) in Deferred Income Taxes Deferred income taxes, net Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Inventories Inventory Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Other Operating Assets Other assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Employee Related Liabilities Accrued payroll and benefits Increase (Decrease) in Property and Other Taxes Payable Other accrued taxes Represents the increase (decrease) during the period in the carrying amount (including both current and noncurrent portions of the accrual) of the liability pertaining to warranty reserve. Increase Decrease in Warranty Reserve Warranty reserve Increase (Decrease) in Contract with Customer, Liability Deferred revenue Increase (Decrease) in Other Current Liabilities Other current liabilities Increase (Decrease) in Income Taxes Payable Prepaid income taxes Net Cash Provided by (Used in) Operating Activities Net cash provided by operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Investing activities: Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Payments to Acquire Other Productive Assets Capitalized intangible assets Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Financing activities: Payments of Dividends Dividends paid Proceeds from Stock Options Exercised Proceeds from exercises of stock options Payment, Tax Withholding, Share-Based Payment Arrangement Taxes paid related to the net share settlement of equity awards Net Cash Provided by (Used in) Financing Activities Net cash used in financing activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase/decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash and cash equivalents, end of period Cash and cash equivalents, beginning of period Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information: Income Taxes Paid, Net Cash paid for income taxes Right-of-Use Asset Obtained in Exchange for Operating Lease Liability ROU asset recognized in exchange for new lease obligation Amount of adjustment of carrying amount of right-of-use asset and liability from operating lease. Operating Lease, Right-of-Use Asset and Liability, Adjustment ROU asset and liability adjustment Amount of cash outflow from operating and short-term lease. Operating and Short-term Lease Payments Operating and short-term lease payments recorded within cash flow provided by operating activities Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Basis of Presentation Revenue Recognition Revenue Recognition Revenue from Contract with Customer [Text Block] Revenue Recognition Basic and Diluted Net Income per Share Basic and Diluted Net Income Per Share Earnings Per Share [Text Block] Basic and Diluted Net Income per Share Inventory, net. Inventory Disclosure [Text Block] Inventory, net Property and Equipment, net Property and Equipment, net Property, Plant and Equipment Disclosure [Text Block] Property and Equipment, net Intangible Assets, net Intangible Assets Disclosure [Text Block] Intangible Assets, net Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Stock-Based Compensation Income Taxes Income Tax Disclosure [Text Block] Income Taxes Leases Lessee, Operating Leases [Text Block] Leases Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Subsequent Events Subsequent Events [Text Block] Subsequent Events Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Concentration Risk, Credit Risk, Policy [Policy Text Block] Certain Significant Risks and Uncertainties Disaggregation of Revenue [Table Text Block] Schedule of disaggregation of revenue by geographic region and revenue type Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Schedule of contract liabilities and changes in the contract liabilities Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of computation of basic and diluted net income per share of common stock Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of stock options and restricted stock units excluded from the calculation of diluted net income per share Schedule of Inventory, Current [Table Text Block] Schedule of inventory Property, Plant and Equipment [Table Text Block] Schedule of property and equipment Long-Lived Assets by Geographic Areas [Table Text Block] Schedule of property and equipment, net, information by geographic region Schedule of Finite-Lived Intangible Assets [Table Text Block] Summary of the components of intangible asset balances Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Schedule of expected annual amortization expense related to intangible assets (excludes in process intangible assets) Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Stock-Based Compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of stock-based compensation Share-Based Payment Arrangement, Activity [Table Text Block] Schedule of stock-based compensation activity Lease, Cost [Table Text Block] Schedule of operating lease cost Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of maturity of operating lease liability Number of Reportable Segments Disaggregation of Revenue [Table] Geographical [Axis] Geographical [Domain] UNITED STATES United States Represents information pertaining to International, a geographic region of the entity. International [Member] International EX-101.PRE 9 irmd-20240930_pre.xml EX-101.PRE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2024	Oct. 31, 2024
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Securities Act File Number	001-36534
Entity Registrant Name	IRADIMED CORPORATION
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	73-1408526
Entity Address, Address Line One	1025 Willa Springs Drive
Entity Address, City or Town	Winter Springs
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	32708
City Area Code	407
Local Phone Number	677-8022
Title of 12(b) Security	Common stock, par value $0.0001
Trading Symbol	IRMD
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		12,673,441
Entity Central Index Key	0001325618
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Amendment Flag	false

XML 12 R2.htm IDEA: XBRL DOCUMENT

CONDENSED BALANCE SHEETS - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 51,721,051	$ 49,762,198
Accounts receivable, net of allowance for credit losses of $277,437 as of September 30, 2024, and $368,835 as of December 31, 2023	10,364,786	12,224,273
Inventory, net	11,251,549	12,821,194
Prepaid expenses and other current assets	948,841	1,193,447
Total current assets	74,286,227	76,001,112
Property and equipment, net	14,155,985	9,288,625
Intangible assets, net	2,891,657	2,519,053
Operating lease right-of-use asset	264,075	2,043,043
Deferred tax asset, net	2,464,604	2,122,816
Other assets	184,213	181,449
Total assets	94,246,761	92,156,098
Current liabilities:
Accounts payable	1,400,544	1,857,091
Accrued payroll and benefits	3,284,226	2,775,103
Other accrued taxes	193,688	103,241
Warranty reserve	118,203	117,463
Deferred revenue	2,555,105	2,570,407
Dividend payable		7,975,997
Current portion of operating lease liabilities	261,244	427,963
Other current liabilities	250,000	250,000
Accrued income taxes		250,041
Total current liabilities	8,063,010	16,327,306
Deferred revenue, non-current	2,748,295	2,793,548
Operating lease liabilities, non-current	2,831	1,615,080
Total liabilities	10,814,136	20,735,934
Stockholders' equity:
Common stock; $0.0001 par value per share; 31,500,000 shares authorized; 12,669,912 shares issued and outstanding as of September 30, 2024, and 12,660,313 shares issued and outstanding as of December 31, 2023	1,267	1,265
Additional paid-in capital	29,886,087	28,160,745
Retained earnings	53,545,271	43,258,154
Total stockholders' equity	83,432,625	71,420,164
Total liabilities and stockholders' equity	$ 94,246,761	$ 92,156,098

XML 13 R3.htm IDEA: XBRL DOCUMENT

CONDENSED BALANCE SHEETS (Parenthetical) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
CONDENSED BALANCE SHEETS
Allowance for credit losses	$ 277,437	$ 368,835
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	31,500,000	31,500,000
Common stock, shares issued	12,669,912	12,660,313
Common stock, shares outstanding	12,669,912	12,660,313

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
CONDENSED STATEMENTS OF OPERATIONS - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
CONDENSED STATEMENTS OF OPERATIONS
Revenue	$ 18,325,959	$ 16,504,640	$ 53,852,954	$ 48,110,120
Cost of revenue	4,134,253	3,667,256	12,263,932	11,364,791
Gross profit	14,191,706	12,837,384	41,589,022	36,745,329
Operating expenses:
General and administrative	3,967,799	3,615,020	12,063,971	10,848,611
Sales and marketing	3,795,320	2,864,469	11,098,945	8,812,872
Research and development	639,467	452,555	2,261,596	2,208,221
Total operating expenses	8,402,586	6,932,044	25,424,512	21,869,704
Income from operations	5,789,120	5,905,340	16,164,510	14,875,625
Other income, net	629,201	503,192	1,766,572	1,180,988
Income before provision for income taxes	6,418,321	6,408,532	17,931,082	16,056,613
Provision for income tax expense	1,368,830	1,341,352	3,843,834	3,403,523
Net income	$ 5,049,491	$ 5,067,180	$ 14,087,248	$ 12,653,090
Net income per share:
Basic (in dollars per share)	$ 0.40	$ 0.40	$ 1.11	$ 1.00
Diluted (in dollars per share)	$ 0.40	$ 0.40	$ 1.10	$ 0.99
Weighted average shares outstanding:
Basic (in shares)	12,669,741	12,602,581	12,665,743	12,597,250
Diluted (in shares)	12,778,446	12,735,837	12,762,346	12,716,988

XML 15 R5.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Common Stock	Additional Paid-In Capital	Retained Earnings	Total
Beginning balances at Dec. 31, 2022	$ 1,259	$ 26,407,446	$ 47,264,282	$ 73,672,987
Beginning balances (in shares) at Dec. 31, 2022	12,591,004
Increase (Decrease) in Stockholders' Equity
Net Income (Loss)			3,406,070	3,406,070
Dividends paid			(13,222,907)	(13,222,907)
Stock-based compensation expense		533,643		533,643
Net share settlement of restricted stock units		(49,878)		(49,878)
Net share settlement of restricted stock units (in shares)	3,572
Ending balances at Mar. 31, 2023	$ 1,259	26,891,211	37,447,445	64,339,915
Ending balances (in shares) at Mar. 31, 2023	12,594,576
Beginning balances at Dec. 31, 2022	$ 1,259	26,407,446	47,264,282	73,672,987
Beginning balances (in shares) at Dec. 31, 2022	12,591,004
Increase (Decrease) in Stockholders' Equity
Net Income (Loss)				12,653,090
Ending balances at Sep. 30, 2023	$ 1,260	27,872,275	46,694,465	74,568,000
Ending balances (in shares) at Sep. 30, 2023	12,602,851
Beginning balances at Mar. 31, 2023	$ 1,259	26,891,211	37,447,445	64,339,915
Beginning balances (in shares) at Mar. 31, 2023	12,594,576
Increase (Decrease) in Stockholders' Equity
Net Income (Loss)			4,179,840	4,179,840
Stock-based compensation expense		568,453		568,453
Net share settlement of restricted stock units	$ 1	(97,106)		(97,105)
Net share settlement of restricted stock units (in shares)	5,965
Exercise of stock options		7,339		7,339
Exercise of stock options (in shares)	1,000
Ending balances at Jun. 30, 2023	$ 1,260	27,369,898	41,627,285	68,998,442
Ending balances (in shares) at Jun. 30, 2023	12,601,541
Increase (Decrease) in Stockholders' Equity
Net Income (Loss)			5,067,180	5,067,180
Stock-based compensation expense		533,749		533,749
Net share settlement of restricted stock units		(31,372)		(31,372)
Net share settlement of restricted stock units (in shares)	1,310
Ending balances at Sep. 30, 2023	$ 1,260	27,872,275	46,694,465	74,568,000
Ending balances (in shares) at Sep. 30, 2023	12,602,851
Beginning balances at Dec. 31, 2023	$ 1,265	28,160,745	43,258,154	71,420,164
Beginning balances (in shares) at Dec. 31, 2023	12,660,313
Increase (Decrease) in Stockholders' Equity
Net Income (Loss)			4,136,533	4,136,533
Stock-based compensation expense		628,640		628,640
Net share settlement of restricted stock units	$ 1	(63,876)		(63,875)
Net share settlement of restricted stock units (in shares)	3,872
Ending balances at Mar. 31, 2024	$ 1,266	28,725,509	47,394,687	76,121,462
Ending balances (in shares) at Mar. 31, 2024	12,664,185
Beginning balances at Dec. 31, 2023	$ 1,265	28,160,745	43,258,154	71,420,164
Beginning balances (in shares) at Dec. 31, 2023	12,660,313
Increase (Decrease) in Stockholders' Equity
Net Income (Loss)				14,087,248
Ending balances at Sep. 30, 2024	$ 1,267	29,886,087	53,545,271	83,432,625
Ending balances (in shares) at Sep. 30, 2024	12,669,912
Beginning balances at Mar. 31, 2024	$ 1,266	28,725,509	47,394,687	76,121,462
Beginning balances (in shares) at Mar. 31, 2024	12,664,185
Increase (Decrease) in Stockholders' Equity
Net Income (Loss)			4,901,224	4,901,224
Dividends paid			(1,899,644)	(1,899,644)
Stock-based compensation expense		609,096		609,096
Net share settlement of restricted stock units	$ 1	(63,946)		(63,945)
Net share settlement of restricted stock units (in shares)	4,581
Exercise of stock options		3,296		3,296
Exercise of stock options (in shares)	335
Ending balances at Jun. 30, 2024	$ 1,267	29,273,955	50,396,267	79,671,489
Ending balances (in shares) at Jun. 30, 2024	12,669,101
Increase (Decrease) in Stockholders' Equity
Net Income (Loss)			5,049,491	5,049,491
Dividends paid			(1,900,487)	(1,900,487)
Stock-based compensation expense		629,965		629,965
Net share settlement of restricted stock units		(17,833)		(17,833)
Net share settlement of restricted stock units (in shares)	811
Ending balances at Sep. 30, 2024	$ 1,267	$ 29,886,087	$ 53,545,271	$ 83,432,625
Ending balances (in shares) at Sep. 30, 2024	12,669,912

XML 16 R6.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - $ / shares	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2023
CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY
Dividends Paid Amount Per Share	$ 0.15	$ 0.15	$ 1.05

XML 17 R7.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
CONDENSED STATEMENTS OF CASH FLOWS - USD ($)	Sep. 30, 2024	Sep. 30, 2023
Operating activities:
Net income	$ 14,087,248	$ 12,653,090
Adjustments to reconcile net income to net cash provided by operating activities:
Allowance for credit losses	(91,398)	136,830
Provision for excess and obsolete inventory	202,140	219,928
Depreciation & amortization	622,790	559,805
Loss on disposal of property and equipment	3,872	12,535
Stock-based compensation	1,867,701	1,635,845
Deferred income taxes, net	(591,829)	(1,102,866)
Changes in operating assets and liabilities:
Accounts receivable	1,950,885	343,054
Inventory	1,278,208	(6,130,592)
Prepaid expenses and other current assets	244,606	(40,055)
Other assets	(2,764)	418,274
Accounts payable	(473,820)	519,648
Accrued payroll and benefits	509,123	(581,699)
Other accrued taxes	90,447	(18,696)
Warranty reserve	740	16,274
Deferred revenue	(60,555)	407,064
Other current liabilities		250,000
Prepaid income taxes		254,093
Net cash provided by operating activities	19,637,394	9,552,532
Investing activities:
Purchases of property and equipment	(5,214,859)	(6,908,607)
Capitalized intangible assets	(545,198)	(465,744)
Net cash used in investing activities	(5,760,057)	(7,374,351)
Financing activities:
Dividends paid	(11,776,128)	(13,222,907)
Proceeds from exercises of stock options	3,296	7,341
Taxes paid related to the net share settlement of equity awards	(145,652)	(178,355)
Net cash used in financing activities	(11,918,484)	(13,393,921)
Net increase/decrease in cash and cash equivalents	1,958,853	(11,215,740)
Cash and cash equivalents, beginning of period	49,762,198	57,960,864
Cash and cash equivalents, end of period	51,721,051	46,745,124
Supplemental disclosure of cash flow information:
Cash paid for income taxes	4,456,827	4,136,152
ROU asset recognized in exchange for new lease obligation		227,983
ROU asset and liability adjustment	1,486,093
Operating and short-term lease payments recorded within cash flow provided by operating activities	$ 612,910	$ 492,528

XML 18 R8.htm IDEA: XBRL DOCUMENT

Basis of Presentation

9 Months Ended

Sep. 30, 2024

Basis of Presentation

Basis of Presentation

1 — Basis of Presentation

Certain Significant Risks and Uncertainties

XML 19 R9.htm IDEA: XBRL DOCUMENT

Revenue Recognition

9 Months Ended

Sep. 30, 2024

Revenue Recognition

Revenue Recognition

2 — Revenue Recognition

Disaggregation of Revenue

We disaggregate revenue from contracts with customers by geographic region and revenue type as we believe it best depicts the nature, amount, timing and uncertainty of our revenue and cash flow.

Revenue information by geographic region is as follows:


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2024		2023		2024		2023

	(unaudited)				(unaudited)
United States	$	15,207,195	$	13,948,368	$	44,101,367	$	38,876,418
International		3,118,764		2,556,272		9,751,587		9,233,702
Total revenue	$	18,325,959	$	16,504,640	$	53,852,954	$	48,110,120

Revenue information by type is as follows:


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2024		2023		2024		2023

	(unaudited)				(unaudited)
Devices:
MRI Compatible Intravenous ("IV") Infusion Pump Systems	$	6,952,142	$	3,905,520	$	19,026,021	$	13,966,905
MRI Compatible Patient Vital Signs Monitoring Systems		5,926,028		7,738,549		17,837,910		18,564,085
Ferro Magnetic Detection Systems		128,505		138,760		744,607		619,539
Total Devices revenue		13,006,675		11,782,829		37,608,538		33,150,529
Disposables, services and other		4,735,066		4,213,666		14,604,879		13,464,278
Amortization of extended warranty agreements		584,218		508,145		1,639,537		1,495,313
Total revenue	$	18,325,959	$	16,504,640	$	53,852,954	$	48,110,120

Contract Liabilities

Our contract liabilities consist of:


	September 30,		December 31,
	2024		2023
	(unaudited)		(audited)
Advance payments from customers	$	216,097	$	508,956
Shipments in-transit		166,700		15,438
Extended warranty agreements		4,920,603		4,835,966
Total	$	5,303,400	$	5,360,360

Changes in the contract liabilities during the periods presented are as follows:


	Deferred
	Revenue
	(unaudited)
Contract liabilities, December 31, 2023	$	5,360,360
Increases due to cash received from customers		3,353,763
Decreases due to recognition of revenue		(3,410,723)
Contract liabilities, September 30, 2024	$	5,303,400


	Deferred
	Revenue
	(unaudited)
Contract liabilities, December 31, 2022	$	4,748,319
Increases due to cash received from customers		3,716,326
Decreases due to recognition of revenue		(3,309,262)
Contract liabilities, September 30, 2023	$	5,155,383

Capitalized Contract Costs

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-9

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-15

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/606/tableOfContent

+ Details

XML 20 R10.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Income per Share

9 Months Ended

Sep. 30, 2024

Basic and Diluted Net Income per Share

Basic and Diluted Net Income per Share

3 — Basic and Diluted Net Income per Share

The following table presents the computation of basic and diluted net income per share of common stock:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023

	(unaudited)				(unaudited)
Net income	$	5,049,491	$	5,067,180	$	14,087,248	$	12,653,090
Weighted-average shares outstanding — Basic		12,669,741		12,602,581		12,665,743		12,597,250
Effect of dilutive securities:
Stock options		2,104		18,727		2,223		18,860
Restricted stock units		63,929		73,478		55,870		63,300
Performance-based restricted stock units		42,672		41,051		38,510		37,578
Weighted-average shares outstanding — Diluted		12,778,446		12,735,837		12,762,346		12,716,988
Basic net income per share	$	0.40	$	0.40	$	1.11	$	1.00
Diluted net income per share	$	0.40	$	0.40	$	1.10	$	0.99

Stock options and restricted stock units excluded from the calculation of diluted net income per share because the effect would have been anti-dilutive are as follows:


	Three Months Ended		Nine Months Ended
	September 30,		September 30,
	2024	2023	2024	2023

	(unaudited)		(unaudited)
Anti-dilutive stock options and restricted stock units	7	438	13	352

XML 21 R11.htm IDEA: XBRL DOCUMENT

Inventory, net

9 Months Ended

Sep. 30, 2024

Inventory, net.

Inventory, net

4 — Inventory, net

Inventory consists of:


	September 30,		December 31,
	2024		2023
	(unaudited)		(audited)
Raw materials	$	9,700,270	$	10,833,004
Work in process		703,363		501,191
Finished goods		1,470,786		1,907,729
Inventory before allowance for excess and obsolete		11,874,419		13,241,924
Allowance for excess and obsolete		(622,870)		(420,730)
Total	$	11,251,549	$	12,821,194

XML 22 R12.htm IDEA: XBRL DOCUMENT

Property and Equipment, net

9 Months Ended

Sep. 30, 2024

Property and Equipment, net

Property and Equipment, net

5 — Property and Equipment, net

Property and equipment consist of:


	September 30,		December 31,
	2024		2023
	(unaudited)		(audited)
Land	$	6,253,790	$	6,253,790
Computer software and hardware		1,516,280		1,380,289
Furniture and fixtures		1,842,773		1,757,129
Leasehold improvements		270,486		270,486
Machinery and equipment		2,624,609		2,438,922
Construction in-process		6,108,204		1,257,844
		18,616,142		13,358,460
Accumulated depreciation		(4,460,157)		(4,069,835)
Total	$	14,155,985	$	9,288,625

Property and equipment, net, information by geographic region is as follows:


	September 30,		December 31,
	2024		2023
	(unaudited)		(audited)
United States	$	13,746,389	$	8,950,580
International		409,596		338,045
Total property and equipment, net	$	14,155,985	$	9,288,625

Long-lived assets held outside of the United States consist principally of tooling and machinery and equipment, which are components of property and equipment, net.

XML 23 R13.htm IDEA: XBRL DOCUMENT

Intangible Assets, net

9 Months Ended

Sep. 30, 2024

Intangible Assets, net

Intangible Assets, net

6 — Intangible Assets, net

The following table summarizes the components of intangible asset balances:


	September 30,		December 31,
	2024		2023
	(unaudited)		(audited)
Patents — in use	$	321,874	$	321,874
Patents — fully amortized		70,164		70,164
Patents — in process		162,233		128,221
Internally developed software — in use		1,840,521		1,773,720
Internally developed software — in process		1,583,423		1,149,409
Trademarks		38,067		27,697
		4,016,282		3,471,085
Accumulated amortization		(1,124,625)		(952,032)
Total	$	2,891,657	$	2,519,053


Three months remaining ending December 31, 2024	$	59,518
2025	$	235,703
2026	$	223,987
2027	$	150,274
2028	$	147,672
Thereafter	$	290,780

XML 24 R14.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

9 Months Ended

Sep. 30, 2024

Fair Value Measurements

Fair Value Measurements

7 — Fair Value Measurements

The fair values of cash equivalents, accounts receivables net, and accounts payable approximate their carrying amounts due to their short duration.

As of September 30, 2024, we did not have any assets or liabilities subject to recurring fair value measurements.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

+ Details

XML 25 R15.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

9 Months Ended

Sep. 30, 2024

Stock-Based Compensation

Stock-Based Compensation

8 — Stock-Based Compensation

Stock-based compensation was recognized as follows in the unaudited Condensed Statements of Operations:


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2024		2023		2024		2023

	(unaudited)				(unaudited)
Cost of revenue	$	62,359	$	63,119	$	178,713	$	187,292
General and administrative		381,339		290,370		1,139,316		871,100
Sales and marketing		135,358		129,340		393,649		435,707
Research and development		50,908		50,919		156,023		141,746
Total	$	629,964	$	533,748	$	1,867,701	$	1,635,845

The following table presents a summary of our equity award activity for the nine months ended September 30, 2024 (shares):


	Nine Months Ended
	September 30, 2024
			Performance
			Based
	Stock	Restricted	Restricted
	Options	Stock Units	Stock Units
Outstanding beginning of period	3,010	141,327	36,792
Awards granted	—	5,353	—
Awards exercised/vested	(335)	(12,601)	—
Awards canceled/ forfeited	—	(2,848)	—
Outstanding end of period	2,675	131,231	36,792

XML 26 R16.htm IDEA: XBRL DOCUMENT

Income Taxes

9 Months Ended

Sep. 30, 2024

Income Taxes

Income Taxes

9 — Income Taxes

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

XML 27 R17.htm IDEA: XBRL DOCUMENT

Leases

9 Months Ended

Sep. 30, 2024

Leases

Leases

10 — Leases

We have entered into operating lease contracts for our manufacturing plant, office space, and various office equipment with two material lease contracts outstanding.

Operating lease cost recognized in the unaudited Condensed Statements of Operations is as follows:


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2024		2023		2024		2023

	(unaudited)				(unaudited)
Cost of revenue	$	59,124	$	58,086	$	176,810	$	174,258
General and administrative		88,666		87,639		265,442		255,562
Sales and marketing		3,309		3,251		9,895		9,752
Research and development		9,167		9,006		27,414		27,019
Total	$	160,266	$	157,982	$	479,561	$	466,591

Lease costs for short-term leases were immaterial for the three and nine months ended September 30, 2024 and 2023.

Maturity of our operating lease liability as of September 30, 2024, is as follows:


Three months remaining ending December 31, 2024	$	152,972
Thereafter		173,514
Total lease payments		326,486
Imputed interest		(62,411)
Present value of lease liability	$	264,075

XML 28 R18.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Sep. 30, 2024

Commitments and Contingencies

Commitments and Contingencies

11 — Commitments and Contingencies

XML 29 R19.htm IDEA: XBRL DOCUMENT

Subsequent Events

9 Months Ended

Sep. 30, 2024

Subsequent Events

Subsequent Events

12 — Subsequent Events

XML 30 R20.htm IDEA: XBRL DOCUMENT

Pay vs Performance Disclosure - USD ($)	3 Months Ended						9 Months Ended
Pay vs Performance Disclosure - USD ($)	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ 5,049,491	$ 4,901,224	$ 4,136,533	$ 5,067,180	$ 4,179,840	$ 3,406,070	$ 14,087,248	$ 12,653,090

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

XML 31 R21.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

XML 32 R22.htm IDEA: XBRL DOCUMENT

Basis of Presentation (Policies)	9 Months Ended
Basis of Presentation (Policies)	Sep. 30, 2024
Basis of Presentation
Basis of Presentation	The accompanying interim condensed financial statements of IRADIMED CORPORATION (“IRADIMED”, the “Company,” “we,” “our” and “us”) have been prepared pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally presented in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. The interim financial information is unaudited, but reflects all normal adjustments that are, in the opinion of management, necessary for the fair presentation of our financial position, results of operations and cash flows for the interim periods presented. Operating results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024, and other interim periods, or future years or periods. The accompanying interim condensed financial statements should be read in conjunction with the financial statements and related footnotes to financial statements included in our 2023 Annual Report. The accounting policies followed in the preparation of these interim condensed financial statements, except as described in Note 1 herein, are consistent in all material respects with those described in Note 1 to the Financial Statements in the 2023 Annual Report. We operate in one reportable segment, which is the development, manufacture and sale of Magnetic Resonance Imaging (“MRI”) compatible medical devices, related accessories, disposables and service for use primarily by hospitals and acute care facilities during MRI procedures.
Certain Significant Risks and Uncertainties	Certain Significant Risks and Uncertainties We market our products to end users in the United States and to third-party distributors internationally. Sales to end users in the United States are generally made on open credit terms. Management maintains an allowance for potential credit losses. We have deposited our cash and cash equivalents with various financial institutions. Our cash and cash equivalents balances exceed federally insured limits regularly throughout the year. We have not incurred any losses related to these balances. Our medical devices require clearance from the FDA and international regulatory agencies prior to commercialized sales. Our future products may not receive required approvals. If we were denied such approvals, or if such approvals were revoked or delayed or if we were unable to timely renew certain approvals for existing products, it would have a materially adverse impact on our business, results of operations and financial condition. Certain key components of our products essential to their functionality are sole-sourced. Any disruption in the availability of these components would have a materially adverse impact on our business, results of operations and financial condition.

XML 33 R23.htm IDEA: XBRL DOCUMENT

Revenue Recognition (Tables)

9 Months Ended

Sep. 30, 2024

Revenue Recognition

Schedule of disaggregation of revenue by geographic region and revenue type


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2024		2023		2024		2023

	(unaudited)				(unaudited)
United States	$	15,207,195	$	13,948,368	$	44,101,367	$	38,876,418
International		3,118,764		2,556,272		9,751,587		9,233,702
Total revenue	$	18,325,959	$	16,504,640	$	53,852,954	$	48,110,120


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2024		2023		2024		2023

	(unaudited)				(unaudited)
Devices:
MRI Compatible Intravenous ("IV") Infusion Pump Systems	$	6,952,142	$	3,905,520	$	19,026,021	$	13,966,905
MRI Compatible Patient Vital Signs Monitoring Systems		5,926,028		7,738,549		17,837,910		18,564,085
Ferro Magnetic Detection Systems		128,505		138,760		744,607		619,539
Total Devices revenue		13,006,675		11,782,829		37,608,538		33,150,529
Disposables, services and other		4,735,066		4,213,666		14,604,879		13,464,278
Amortization of extended warranty agreements		584,218		508,145		1,639,537		1,495,313
Total revenue	$	18,325,959	$	16,504,640	$	53,852,954	$	48,110,120

Schedule of contract liabilities and changes in the contract liabilities


	September 30,		December 31,
	2024		2023
	(unaudited)		(audited)
Advance payments from customers	$	216,097	$	508,956
Shipments in-transit		166,700		15,438
Extended warranty agreements		4,920,603		4,835,966
Total	$	5,303,400	$	5,360,360


	Deferred
	Revenue
	(unaudited)
Contract liabilities, December 31, 2023	$	5,360,360
Increases due to cash received from customers		3,353,763
Decreases due to recognition of revenue		(3,410,723)
Contract liabilities, September 30, 2024	$	5,303,400


	Deferred
	Revenue
	(unaudited)
Contract liabilities, December 31, 2022	$	4,748,319
Increases due to cash received from customers		3,716,326
Decreases due to recognition of revenue		(3,309,262)
Contract liabilities, September 30, 2023	$	5,155,383

XML 34 R24.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Income per Share (Tables)

9 Months Ended

Sep. 30, 2024

Basic and Diluted Net Income per Share

Schedule of computation of basic and diluted net income per share of common stock


	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023

	(unaudited)				(unaudited)
Net income	$	5,049,491	$	5,067,180	$	14,087,248	$	12,653,090
Weighted-average shares outstanding — Basic		12,669,741		12,602,581		12,665,743		12,597,250
Effect of dilutive securities:
Stock options		2,104		18,727		2,223		18,860
Restricted stock units		63,929		73,478		55,870		63,300
Performance-based restricted stock units		42,672		41,051		38,510		37,578
Weighted-average shares outstanding — Diluted		12,778,446		12,735,837		12,762,346		12,716,988
Basic net income per share	$	0.40	$	0.40	$	1.11	$	1.00
Diluted net income per share	$	0.40	$	0.40	$	1.10	$	0.99

Schedule of stock options and restricted stock units excluded from the calculation of diluted net income per share


	Three Months Ended		Nine Months Ended
	September 30,		September 30,
	2024	2023	2024	2023

	(unaudited)		(unaudited)
Anti-dilutive stock options and restricted stock units	7	438	13	352

XML 35 R25.htm IDEA: XBRL DOCUMENT

Inventory, net (Tables)

9 Months Ended

Sep. 30, 2024

Inventory, net.

Schedule of inventory


	September 30,		December 31,
	2024		2023
	(unaudited)		(audited)
Raw materials	$	9,700,270	$	10,833,004
Work in process		703,363		501,191
Finished goods		1,470,786		1,907,729
Inventory before allowance for excess and obsolete		11,874,419		13,241,924
Allowance for excess and obsolete		(622,870)		(420,730)
Total	$	11,251,549	$	12,821,194

XML 36 R26.htm IDEA: XBRL DOCUMENT

Property and Equipment, net (Tables)

9 Months Ended

Sep. 30, 2024

Property and Equipment, net

Schedule of property and equipment


	September 30,		December 31,
	2024		2023
	(unaudited)		(audited)
Land	$	6,253,790	$	6,253,790
Computer software and hardware		1,516,280		1,380,289
Furniture and fixtures		1,842,773		1,757,129
Leasehold improvements		270,486		270,486
Machinery and equipment		2,624,609		2,438,922
Construction in-process		6,108,204		1,257,844
		18,616,142		13,358,460
Accumulated depreciation		(4,460,157)		(4,069,835)
Total	$	14,155,985	$	9,288,625

Schedule of property and equipment, net, information by geographic region


	September 30,		December 31,
	2024		2023
	(unaudited)		(audited)
United States	$	13,746,389	$	8,950,580
International		409,596		338,045
Total property and equipment, net	$	14,155,985	$	9,288,625

XML 37 R27.htm IDEA: XBRL DOCUMENT

Intangible Assets, net (Tables)

9 Months Ended

Sep. 30, 2024

Intangible Assets, net

Summary of the components of intangible asset balances


	September 30,		December 31,
	2024		2023
	(unaudited)		(audited)
Patents — in use	$	321,874	$	321,874
Patents — fully amortized		70,164		70,164
Patents — in process		162,233		128,221
Internally developed software — in use		1,840,521		1,773,720
Internally developed software — in process		1,583,423		1,149,409
Trademarks		38,067		27,697
		4,016,282		3,471,085
Accumulated amortization		(1,124,625)		(952,032)
Total	$	2,891,657	$	2,519,053

Schedule of expected annual amortization expense related to intangible assets (excludes in process intangible assets)


Three months remaining ending December 31, 2024	$	59,518
2025	$	235,703
2026	$	223,987
2027	$	150,274
2028	$	147,672
Thereafter	$	290,780

XML 38 R28.htm IDEA: XBRL DOCUMENT

Stock Based Compensation (Tables)

9 Months Ended

Sep. 30, 2024

Stock-Based Compensation

Schedule of stock-based compensation


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2024		2023		2024		2023

	(unaudited)				(unaudited)
Cost of revenue	$	62,359	$	63,119	$	178,713	$	187,292
General and administrative		381,339		290,370		1,139,316		871,100
Sales and marketing		135,358		129,340		393,649		435,707
Research and development		50,908		50,919		156,023		141,746
Total	$	629,964	$	533,748	$	1,867,701	$	1,635,845

Schedule of stock-based compensation activity


	Nine Months Ended
	September 30, 2024
			Performance
			Based
	Stock	Restricted	Restricted
	Options	Stock Units	Stock Units
Outstanding beginning of period	3,010	141,327	36,792
Awards granted	—	5,353	—
Awards exercised/vested	(335)	(12,601)	—
Awards canceled/ forfeited	—	(2,848)	—
Outstanding end of period	2,675	131,231	36,792

XML 39 R29.htm IDEA: XBRL DOCUMENT

Leases (Tables)

9 Months Ended

Sep. 30, 2024

Leases

Schedule of operating lease cost


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2024		2023		2024		2023

	(unaudited)				(unaudited)
Cost of revenue	$	59,124	$	58,086	$	176,810	$	174,258
General and administrative		88,666		87,639		265,442		255,562
Sales and marketing		3,309		3,251		9,895		9,752
Research and development		9,167		9,006		27,414		27,019
Total	$	160,266	$	157,982	$	479,561	$	466,591

Schedule of maturity of operating lease liability


Three months remaining ending December 31, 2024	$	152,972
Thereafter		173,514
Total lease payments		326,486
Imputed interest		(62,411)
Present value of lease liability	$	264,075

XML 40 R30.htm IDEA: XBRL DOCUMENT

Basis of Presentation (Details)	9 Months Ended
Basis of Presentation (Details)	Sep. 30, 2024 segment
Basis of Presentation
Number of Reportable Segments	1

XML 41 R31.htm IDEA: XBRL DOCUMENT

Revenue Recognition - Information by geographic region (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Contract Liabilities
Total revenue	$ 18,325,959	$ 16,504,640	$ 53,852,954	$ 48,110,120
United States
Contract Liabilities
Total revenue	15,207,195	13,948,368	44,101,367	38,876,418
International
Contract Liabilities
Total revenue	$ 3,118,764	$ 2,556,272	$ 9,751,587	$ 9,233,702

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

XML 42 R32.htm IDEA: XBRL DOCUMENT

Revenue Recognition - Information by type (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Disaggregation of Revenue
Total Devices revenue	$ 13,006,675	$ 11,782,829	$ 37,608,538	$ 33,150,529
Disposables, services and other	4,735,066	4,213,666	14,604,879	13,464,278
Amortization of extended warranty agreements	584,218	508,145	1,639,537	1,495,313
Total revenue	18,325,959	16,504,640	53,852,954	48,110,120
MRI Compatible Intravenous ("IV") Infusion Pump Systems
Disaggregation of Revenue
Total Devices revenue	6,952,142	3,905,520	19,026,021	13,966,905
MRI Compatible Patient Vital Signs Monitoring Systems
Disaggregation of Revenue
Total Devices revenue	5,926,028	7,738,549	17,837,910	18,564,085
Ferro Magnetic Detection Systems
Disaggregation of Revenue
Total Devices revenue	$ 128,505	$ 138,760	$ 744,607	$ 619,539

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

- Definition

+ References

+ Details

XML 43 R33.htm IDEA: XBRL DOCUMENT

Revenue Recognition - Contract liabilities (Details) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Abstract]
Advance payments from customers	$ 216,097		$ 508,956
Shipments in-transit	166,700		15,438
Extended warranty agreements	4,920,603		4,835,966
Total	5,303,400	$ 5,155,383	$ 5,360,360
Changes in contract liabilities
Contract liabilities, beginning balance	5,360,360	4,748,319
Increases due to cash received from customers	3,353,763	3,716,326
Decreases due to recognition of revenue	(3,410,723)	(3,309,262)
Contract liabilities, ending balance	$ 5,303,400	$ 5,155,383

XML 44 R34.htm IDEA: XBRL DOCUMENT

Revenue Recognition- Capitalized contract costs (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Revenue Recognition
Capitalized contract costs	$ 164,898	$ 162,134

XML 45 R35.htm IDEA: XBRL DOCUMENT

Basic and diluted net income per share (Details) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Basic and Diluted Net Income Per Share
Common stock, par value (in dollars per share)	$ 0.0001						$ 0.0001		$ 0.0001
Net Income (Loss)	$ 5,049,491	$ 4,901,224	$ 4,136,533	$ 5,067,180	$ 4,179,840	$ 3,406,070	$ 14,087,248	$ 12,653,090
Weighted-average shares outstanding - Basic	12,669,741			12,602,581			12,665,743	12,597,250
Effect of dilutive securities:
Stock options	2,104			18,727			2,223	18,860
Restricted stock units	63,929			73,478			55,870	63,300
Performance-based restricted stock units	42,672			41,051			38,510	37,578
Weighted-average shares outstanding - Diluted (in shares)	12,778,446			12,735,837			12,762,346	12,716,988
Basic net income per share (in dollars per share)	$ 0.40			$ 0.40			$ 1.11	$ 1.00
Diluted net income per share (in dollars per share)	$ 0.40			$ 0.40			$ 1.10	$ 0.99
Anti-dilutive stock
Anti-dilutive stock options and restricted stock units	7			438			13	352

XML 46 R36.htm IDEA: XBRL DOCUMENT

Inventory, net (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Inventory, net.
Raw materials	$ 9,700,270	$ 10,833,004
Work in process	703,363	501,191
Finished goods	1,470,786	1,907,729
Inventory before allowance for excess and obsolete	11,874,419	13,241,924
Allowance for excess and obsolete	(622,870)	(420,730)
Total	$ 11,251,549	$ 12,821,194

XML 47 R37.htm IDEA: XBRL DOCUMENT

Property and Equipment, net (Details) - USD ($)	3 Months Ended		9 Months Ended
Property and Equipment, net (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Property and equipment, net
Property and equipment, gross	$ 18,616,142		$ 18,616,142		$ 13,358,460
Accumulated depreciation	(4,460,157)		(4,460,157)		(4,069,835)
Total	14,155,985		14,155,985		9,288,625
Depreciation expense of property and equipment	139,840	$ 164,595	450,194	$ 484,094
Land
Property and equipment, net
Property and equipment, gross	6,253,790		6,253,790		6,253,790
Computer software and hardware
Property and equipment, net
Property and equipment, gross	1,516,280		1,516,280		1,380,289
Furniture and fixtures
Property and equipment, net
Property and equipment, gross	1,842,773		1,842,773		1,757,129
Leasehold improvements
Property and equipment, net
Property and equipment, gross	270,486		270,486		270,486
Machinery and equipment
Property and equipment, net
Property and equipment, gross	2,624,609		2,624,609		2,438,922
Construction in-process
Property and equipment, net
Property and equipment, gross	$ 6,108,204		$ 6,108,204		$ 1,257,844

XML 48 R38.htm IDEA: XBRL DOCUMENT

Property and Equipment, net - geographic region (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Property and equipment, net
Total property and equipment, net	$ 14,155,985	$ 9,288,625
United States
Property and equipment, net
Total property and equipment, net	13,746,389	8,950,580
International
Property and equipment, net
Total property and equipment, net	$ 409,596	$ 338,045

XML 49 R39.htm IDEA: XBRL DOCUMENT

Intangible Assets, net (Details) - USD ($)	3 Months Ended		9 Months Ended
Intangible Assets, net (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Intangible Assets, net
Intangible Assets, gross	$ 4,016,282		$ 4,016,282		$ 3,471,085
Accumulated amortization	(1,124,625)		(1,124,625)		(952,032)
Total	2,891,657		2,891,657		2,519,053
Amortization expense of intangible assets	57,731	$ 25,236	172,596	$ 75,708
Expected annual amortization expense
Three months remaining ending December 31, 2024	59,518		59,518
2025	235,703		235,703
2026	223,987		223,987
2027	150,274		150,274
2028	147,672		147,672
Thereafter	290,780		290,780
Patents - in use
Intangible Assets, net
Intangible Assets, gross	321,874		321,874		321,874
Patents - fully amortized
Intangible Assets, net
Intangible Assets, gross	70,164		70,164		70,164
Patents - in process
Intangible Assets, net
Intangible Assets, gross	162,233		162,233		128,221
Internally developed software - in use
Intangible Assets, net
Intangible Assets, gross	1,840,521		1,840,521		1,773,720
Internally developed software - in process
Intangible Assets, net
Intangible Assets, gross	1,583,423		1,583,423		1,149,409
Trademarks
Intangible Assets, net
Intangible Assets, gross	$ 38,067		$ 38,067		$ 27,697

XML 50 R40.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Stock-based compensation expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Stock-Based Compensation
Total stock-based compensation expense	$ 629,964	$ 533,748	$ 1,867,701	$ 1,635,845
Cost of revenue
Stock-Based Compensation
Total stock-based compensation expense	62,359	63,119	178,713	187,292
General and administrative
Stock-Based Compensation
Total stock-based compensation expense	381,339	290,370	1,139,316	871,100
Sales and marketing
Stock-Based Compensation
Total stock-based compensation expense	135,358	129,340	393,649	435,707
Research and development
Stock-Based Compensation
Total stock-based compensation expense	$ 50,908	$ 50,919	$ 156,023	$ 141,746

XML 51 R41.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Restricted Stock Units (Details) - Restricted Stock Units	9 Months Ended
	Sep. 30, 2024 USD ($)
Stock-Based Compensation
Unrecognized compensation cost for unvested award	$ 2,875,176
Weighted-average period of unrecognized compensation cost expected to be recognized	2 years 1 month 20 days

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

XML 52 R42.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Performance-Based Restricted Stock Units - Narrative (Details) - Performance Based Restricted Stock Units	9 Months Ended
	Sep. 30, 2024 USD ($)
Stock-Based Compensation
Unrecognized compensation cost for unvested award	$ 866,155
Weighted-average period of unrecognized compensation cost expected to be recognized	1 year 9 months 25 days

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

XML 53 R43.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Stock Options and Restricted Stock Units Activity (Details)	9 Months Ended
	Sep. 30, 2024 shares
Stock Options
Stock Options
Outstanding beginning of period (in shares)	3,010
Awards exercised/vested (in shares)	(335)
Outstanding end of period (in shares)	2,675
Restricted Stock Units
Stock Options
Outstanding beginning of period (in shares)	141,327
Awards granted (in shares)	5,353
Awards exercised/vested (in shares)	(12,601)
Awards canceled/ forfeited (in shares)	(2,848)
Outstanding end of period (in shares)	131,231
Performance Based Restricted Stock Units
Stock Options
Outstanding beginning of period (in shares)	36,792
Outstanding end of period (in shares)	36,792

XML 54 R44.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) - USD ($)	3 Months Ended		9 Months Ended
Income Taxes (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Taxes
Provision for income tax expense	$ 1,368,830	$ 1,341,352	$ 3,843,834	$ 3,403,523
Effective rate (as a percent)	21.30%	20.90%	21.40%	21.20%

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (a)
-SubTopic 20
-Topic 740
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

XML 55 R45.htm IDEA: XBRL DOCUMENT

Leases (Details)		1 Months Ended		3 Months Ended		9 Months Ended
Leases (Details)	May 29, 2024 USD ($)	Feb. 28, 2023 USD ($) item	Jan. 31, 2014 USD ($)	Sep. 30, 2024 USD ($) item	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) item	Sep. 30, 2023 USD ($)
Leases
ROU asset and liability adjustment						$ 1,486,093
Lessee, operating lease, existence of residual value guarantee						false
Number of material lease contracts outstanding \| item				2		2
Winter Springs, Florida Facility
Leases
Monthly base rent		$ 10,055
Operating lease paid				$ 30,165	$ 30,165	$ 90,495	$ 83,140
Non-cancelable operating lease term		2 years
Number of non-cancelable operating leases entered \| item		2
Susi, LLC
Leases
Monthly base rent	$ 34,133
ROU asset and liability adjustment	$ 1,480,000
Related Party [Member] \| Susi, LLC
Leases
Operating lease paid				$ 160,266	$ 127,817	$ 479,561	$ 386,958
Related Party [Member] \| Susi, LLC \| Winter Springs, Florida Facility
Leases
Monthly base rent			$ 34,133
Renewal term of lease beginning in 2019			5 years

XML 56 R46.htm IDEA: XBRL DOCUMENT

Leases - Operating lease cost (Details) - USD ($)	3 Months Ended		9 Months Ended
Leases - Operating lease cost (Details) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Leases
Operating lease cost	$ 160,266	$ 157,982	$ 479,561	$ 466,591
Cost of revenue
Leases
Operating lease cost	59,124	58,086	176,810	174,258
General and Administrative Expense [Member]
Leases
Operating lease cost	88,666	87,639	265,442	255,562
Selling and Marketing Expense [Member]
Leases
Operating lease cost	3,309	3,251	9,895	9,752
Research and Development Expense [Member]
Leases
Operating lease cost	$ 9,167	$ 9,006	$ 27,414	$ 27,019

XML 57 R47.htm IDEA: XBRL DOCUMENT

Leases - Maturity of operating lease liability (Details)	Sep. 30, 2024 USD ($)
Operating leases
Three months remaining ending December 31, 2024	$ 152,972
Thereafter	173,514
Total lease payments	326,486
Imputed interest	(62,411)
Present value of lease liability	$ 264,075

XML 58 R48.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Purchase commitments
Purchase commitments	$ 6,921,468	$ 8,217,571
Legal matters accrued	$ 250,000	$ 250,000

XML 59 R49.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details) - O 2024 Q2 Dividends [Member]	Oct. 30, 2024 $ / shares
Subsequent Events
Dividends payable, date declared	Oct. 30, 2024
Cash dividend per share declared	$ 0.15
Dividends payable, payment date	Nov. 25, 2024
Dividends payable, record date	Nov. 15, 2024

EXCEL 60 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 62 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 147 209 1 false 31 0 false 6 false false R1.htm 995200090 - Document - Document and Entity Information Sheet http://iradimed.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 995200100 - Statement - CONDENSED BALANCE SHEETS Sheet http://iradimed.com/role/StatementCondensedBalanceSheets CONDENSED BALANCE SHEETS Statements 2 false false R3.htm 995200105 - Statement - CONDENSED BALANCE SHEETS (Parenthetical) Sheet http://iradimed.com/role/StatementCondensedBalanceSheetsParenthetical CONDENSED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 995200200 - Statement - CONDENSED STATEMENTS OF OPERATIONS Sheet http://iradimed.com/role/StatementCondensedStatementsOfOperations CONDENSED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 995200300 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 995200305 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Sheet http://iradimed.com/role/StatementCondensedStatementsOfStockholdersEquityParenthetical CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Statements 6 false false R7.htm 995200400 - Statement - CONDENSED STATEMENTS OF CASH FLOWS Sheet http://iradimed.com/role/StatementCondensedStatementsOfCashFlows CONDENSED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 995210101 - Disclosure - Basis of Presentation Sheet http://iradimed.com/role/DisclosureBasisOfPresentation Basis of Presentation Notes 8 false false R9.htm 995210201 - Disclosure - Revenue Recognition Sheet http://iradimed.com/role/DisclosureRevenueRecognition Revenue Recognition Notes 9 false false R10.htm 995210301 - Disclosure - Basic and Diluted Net Income per Share Sheet http://iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShare Basic and Diluted Net Income per Share Notes 10 false false R11.htm 995210401 - Disclosure - Inventory, net Sheet http://iradimed.com/role/DisclosureInventoryNet Inventory, net Notes 11 false false R12.htm 995210501 - Disclosure - Property and Equipment, net Sheet http://iradimed.com/role/DisclosurePropertyAndEquipmentNet Property and Equipment, net Notes 12 false false R13.htm 995210601 - Disclosure - Intangible Assets, net Sheet http://iradimed.com/role/DisclosureIntangibleAssetsNet Intangible Assets, net Notes 13 false false R14.htm 995210701 - Disclosure - Fair Value Measurements Sheet http://iradimed.com/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 14 false false R15.htm 995210801 - Disclosure - Stock-Based Compensation Sheet http://iradimed.com/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 15 false false R16.htm 995210901 - Disclosure - Income Taxes Sheet http://iradimed.com/role/DisclosureIncomeTaxes Income Taxes Notes 16 false false R17.htm 995211001 - Disclosure - Leases Sheet http://iradimed.com/role/DisclosureLeases Leases Notes 17 false false R18.htm 995211101 - Disclosure - Commitments and Contingencies Sheet http://iradimed.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 18 false false R19.htm 995211201 - Disclosure - Subsequent Events Sheet http://iradimed.com/role/DisclosureSubsequentEvents Subsequent Events Notes 19 false false R20.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 20 false false R21.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 21 false false R22.htm 99920102 - Disclosure - Basis of Presentation (Policies) Sheet http://iradimed.com/role/DisclosureBasisOfPresentationPolicies Basis of Presentation (Policies) Policies 22 false false R23.htm 99930203 - Disclosure - Revenue Recognition (Tables) Sheet http://iradimed.com/role/DisclosureRevenueRecognitionTables Revenue Recognition (Tables) Tables http://iradimed.com/role/DisclosureRevenueRecognition 23 false false R24.htm 99930303 - Disclosure - Basic and Diluted Net Income per Share (Tables) Sheet http://iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareTables Basic and Diluted Net Income per Share (Tables) Tables http://iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShare 24 false false R25.htm 99930403 - Disclosure - Inventory, net (Tables) Sheet http://iradimed.com/role/DisclosureInventoryNetTables Inventory, net (Tables) Tables http://iradimed.com/role/DisclosureInventoryNet 25 false false R26.htm 99930503 - Disclosure - Property and Equipment, net (Tables) Sheet http://iradimed.com/role/DisclosurePropertyAndEquipmentNetTables Property and Equipment, net (Tables) Tables http://iradimed.com/role/DisclosurePropertyAndEquipmentNet 26 false false R27.htm 99930603 - Disclosure - Intangible Assets, net (Tables) Sheet http://iradimed.com/role/DisclosureIntangibleAssetsNetTables Intangible Assets, net (Tables) Tables http://iradimed.com/role/DisclosureIntangibleAssetsNet 27 false false R28.htm 99930803 - Disclosure - Stock Based Compensation (Tables) Sheet http://iradimed.com/role/DisclosureStockBasedCompensationTables Stock Based Compensation (Tables) Tables 28 false false R29.htm 99931003 - Disclosure - Leases (Tables) Sheet http://iradimed.com/role/DisclosureLeasesTables Leases (Tables) Tables http://iradimed.com/role/DisclosureLeases 29 false false R30.htm 99940101 - Disclosure - Basis of Presentation (Details) Sheet http://iradimed.com/role/DisclosureBasisOfPresentationDetails Basis of Presentation (Details) Details http://iradimed.com/role/DisclosureBasisOfPresentationPolicies 30 false false R31.htm 99940201 - Disclosure - Revenue Recognition - Information by geographic region (Details) Sheet http://iradimed.com/role/DisclosureRevenueRecognitionInformationByGeographicRegionDetails Revenue Recognition - Information by geographic region (Details) Details 31 false false R32.htm 99940202 - Disclosure - Revenue Recognition - Information by type (Details) Sheet http://iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails Revenue Recognition - Information by type (Details) Details 32 false false R33.htm 99940203 - Disclosure - Revenue Recognition - Contract liabilities (Details) Sheet http://iradimed.com/role/DisclosureRevenueRecognitionContractLiabilitiesDetails Revenue Recognition - Contract liabilities (Details) Details 33 false false R34.htm 99940204 - Disclosure - Revenue Recognition- Capitalized contract costs (Details) Sheet http://iradimed.com/role/DisclosureRevenueRecognitionCapitalizedContractCostsDetails Revenue Recognition- Capitalized contract costs (Details) Details 34 false false R35.htm 99940301 - Disclosure - Basic and diluted net income per share (Details) Sheet http://iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails Basic and diluted net income per share (Details) Details 35 false false R36.htm 99940401 - Disclosure - Inventory, net (Details) Sheet http://iradimed.com/role/DisclosureInventoryNetDetails Inventory, net (Details) Details http://iradimed.com/role/DisclosureInventoryNetTables 36 false false R37.htm 99940501 - Disclosure - Property and Equipment, net (Details) Sheet http://iradimed.com/role/DisclosurePropertyAndEquipmentNetDetails Property and Equipment, net (Details) Details http://iradimed.com/role/DisclosurePropertyAndEquipmentNetTables 37 false false R38.htm 99940502 - Disclosure - Property and Equipment, net - geographic region (Details) Sheet http://iradimed.com/role/DisclosurePropertyAndEquipmentNetGeographicRegionDetails Property and Equipment, net - geographic region (Details) Details 38 false false R39.htm 99940601 - Disclosure - Intangible Assets, net (Details) Sheet http://iradimed.com/role/DisclosureIntangibleAssetsNetDetails Intangible Assets, net (Details) Details http://iradimed.com/role/DisclosureIntangibleAssetsNetTables 39 false false R40.htm 99940801 - Disclosure - Stock-Based Compensation - Stock-based compensation expense (Details) Sheet http://iradimed.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails Stock-Based Compensation - Stock-based compensation expense (Details) Details 40 false false R41.htm 99940802 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details) Sheet http://iradimed.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails Stock-Based Compensation - Restricted Stock Units (Details) Details 41 false false R42.htm 99940803 - Disclosure - Stock-Based Compensation - Performance-Based Restricted Stock Units - Narrative (Details) Sheet http://iradimed.com/role/DisclosureStockBasedCompensationPerformanceBasedRestrictedStockUnitsNarrativeDetails Stock-Based Compensation - Performance-Based Restricted Stock Units - Narrative (Details) Details 42 false false R43.htm 99940804 - Disclosure - Stock-Based Compensation - Stock Options and Restricted Stock Units Activity (Details) Sheet http://iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails Stock-Based Compensation - Stock Options and Restricted Stock Units Activity (Details) Details 43 false false R44.htm 99940901 - Disclosure - Income Taxes (Details) Sheet http://iradimed.com/role/DisclosureIncomeTaxesDetails Income Taxes (Details) Details http://iradimed.com/role/DisclosureIncomeTaxes 44 false false R45.htm 99941001 - Disclosure - Leases (Details) Sheet http://iradimed.com/role/DisclosureLeasesDetails Leases (Details) Details http://iradimed.com/role/DisclosureLeasesTables 45 false false R46.htm 99941002 - Disclosure - Leases - Operating lease cost (Details) Sheet http://iradimed.com/role/DisclosureLeasesOperatingLeaseCostDetails Leases - Operating lease cost (Details) Details 46 false false R47.htm 99941003 - Disclosure - Leases - Maturity of operating lease liability (Details) Sheet http://iradimed.com/role/DisclosureLeasesMaturityOfOperatingLeaseLiabilityDetails Leases - Maturity of operating lease liability (Details) Details 47 false false R48.htm 99941101 - Disclosure - Commitments and Contingencies (Details) Sheet http://iradimed.com/role/DisclosureCommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://iradimed.com/role/DisclosureCommitmentsAndContingencies 48 false false R49.htm 99941201 - Disclosure - Subsequent Events (Details) Sheet http://iradimed.com/role/DisclosureSubsequentEventsDetails Subsequent Events (Details) Details http://iradimed.com/role/DisclosureSubsequentEvents 49 false false All Reports Book All Reports irmd-20240930.xsd irmd-20240930_cal.xml irmd-20240930_def.xml irmd-20240930_lab.xml irmd-20240930_pre.xml irmd-20240930x10q.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 67 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "irmd-20240930x10q.htm": { "nsprefix": "irmd", "nsuri": "http://iradimed.com/20240930", "dts": { "schema": { "local": [ "irmd-20240930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "irmd-20240930_cal.xml" ] }, "definitionLink": { "local": [ "irmd-20240930_def.xml" ] }, "labelLink": { "local": [ "irmd-20240930_lab.xml" ] }, "presentationLink": { "local": [ "irmd-20240930_pre.xml" ] }, "inline": { "local": [ "irmd-20240930x10q.htm" ] } }, "keyStandard": 191, "keyCustom": 18, "axisStandard": 10, "axisCustom": 0, "memberStandard": 17, "memberCustom": 14, "hidden": { "total": 7, "http://xbrl.sec.gov/dei/2024": 5, "http://fasb.org/us-gaap/2024": 2 }, "contextCount": 147, "entityCount": 1, "segmentCount": 31, "elementCount": 418, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 522, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://iradimed.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://iradimed.com/role/StatementCondensedBalanceSheets", "longName": "995200100 - Statement - CONDENSED BALANCE SHEETS", "shortName": "CONDENSED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_9_30_2024_c7DkxU9n4kG1FWkteF2Frg", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_c7DkxU9n4kG1FWkteF2Frg", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R3": { "role": "http://iradimed.com/role/StatementCondensedBalanceSheetsParenthetical", "longName": "995200105 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_9_30_2024_c7DkxU9n4kG1FWkteF2Frg", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_c7DkxU9n4kG1FWkteF2Frg", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://iradimed.com/role/StatementCondensedStatementsOfOperations", "longName": "995200200 - Statement - CONDENSED STATEMENTS OF OPERATIONS", "shortName": "CONDENSED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_hCOijSb9akCf77GpRIPuFQ", "name": "us-gaap:Revenues", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_hCOijSb9akCf77GpRIPuFQ", "name": "us-gaap:Revenues", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R5": { "role": "http://iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity", "longName": "995200300 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY", "shortName": "CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__kV2G3L_vkSZwvVhjAb4Gw", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_r3r63mb5IkiEOo5cdzrqEA", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "unique": true } }, "R6": { "role": "http://iradimed.com/role/StatementCondensedStatementsOfStockholdersEquityParenthetical", "longName": "995200305 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)", "shortName": "CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "As_Of_9_30_2024_c7DkxU9n4kG1FWkteF2Frg", "name": "irmd:DividendsPaidAmountPerShare", "unitRef": "Unit_Divide_USD_shares_kXSTsTg9_kWRVGEUL0DbAw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_c7DkxU9n4kG1FWkteF2Frg", "name": "irmd:DividendsPaidAmountPerShare", "unitRef": "Unit_Divide_USD_shares_kXSTsTg9_kWRVGEUL0DbAw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows", "longName": "995200400 - Statement - CONDENSED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://iradimed.com/role/DisclosureBasisOfPresentation", "longName": "995210101 - Disclosure - Basis of Presentation", "shortName": "Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://iradimed.com/role/DisclosureRevenueRecognition", "longName": "995210201 - Disclosure - Revenue Recognition", "shortName": "Revenue Recognition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShare", "longName": "995210301 - Disclosure - Basic and Diluted Net Income per Share", "shortName": "Basic and Diluted Net Income per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://iradimed.com/role/DisclosureInventoryNet", "longName": "995210401 - Disclosure - Inventory, net", "shortName": "Inventory, net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://iradimed.com/role/DisclosurePropertyAndEquipmentNet", "longName": "995210501 - Disclosure - Property and Equipment, net", "shortName": "Property and Equipment, net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://iradimed.com/role/DisclosureIntangibleAssetsNet", "longName": "995210601 - Disclosure - Intangible Assets, net", "shortName": "Intangible Assets, net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://iradimed.com/role/DisclosureFairValueMeasurements", "longName": "995210701 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://iradimed.com/role/DisclosureStockBasedCompensation", "longName": "995210801 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://iradimed.com/role/DisclosureIncomeTaxes", "longName": "995210901 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://iradimed.com/role/DisclosureLeases", "longName": "995211001 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://iradimed.com/role/DisclosureCommitmentsAndContingencies", "longName": "995211101 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://iradimed.com/role/DisclosureSubsequentEvents", "longName": "995211201 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_hCOijSb9akCf77GpRIPuFQ", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R21": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_hCOijSb9akCf77GpRIPuFQ", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_hCOijSb9akCf77GpRIPuFQ", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://iradimed.com/role/DisclosureBasisOfPresentationPolicies", "longName": "99920102 - Disclosure - Basis of Presentation (Policies)", "shortName": "Basis of Presentation (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://iradimed.com/role/DisclosureRevenueRecognitionTables", "longName": "99930203 - Disclosure - Revenue Recognition (Tables)", "shortName": "Revenue Recognition (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareTables", "longName": "99930303 - Disclosure - Basic and Diluted Net Income per Share (Tables)", "shortName": "Basic and Diluted Net Income per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://iradimed.com/role/DisclosureInventoryNetTables", "longName": "99930403 - Disclosure - Inventory, net (Tables)", "shortName": "Inventory, net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://iradimed.com/role/DisclosurePropertyAndEquipmentNetTables", "longName": "99930503 - Disclosure - Property and Equipment, net (Tables)", "shortName": "Property and Equipment, net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://iradimed.com/role/DisclosureIntangibleAssetsNetTables", "longName": "99930603 - Disclosure - Intangible Assets, net (Tables)", "shortName": "Intangible Assets, net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://iradimed.com/role/DisclosureStockBasedCompensationTables", "longName": "99930803 - Disclosure - Stock Based Compensation (Tables)", "shortName": "Stock Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://iradimed.com/role/DisclosureLeasesTables", "longName": "99931003 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://iradimed.com/role/DisclosureBasisOfPresentationDetails", "longName": "99940101 - Disclosure - Basis of Presentation (Details)", "shortName": "Basis of Presentation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "Unit_Standard_segment_zJG8-o6UEkGU8tOOK5FAtw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "Unit_Standard_segment_zJG8-o6UEkGU8tOOK5FAtw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://iradimed.com/role/DisclosureRevenueRecognitionInformationByGeographicRegionDetails", "longName": "99940201 - Disclosure - Revenue Recognition - Information by geographic region (Details)", "shortName": "Revenue Recognition - Information by geographic region (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_hCOijSb9akCf77GpRIPuFQ", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_srt_StatementGeographicalAxis_country_US_WAgBcVaN60SJHEb43YBkNg", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "unique": true } }, "R32": { "role": "http://iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails", "longName": "99940202 - Disclosure - Revenue Recognition - Information by type (Details)", "shortName": "Revenue Recognition - Information by type (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_hCOijSb9akCf77GpRIPuFQ", "name": "irmd:RevenueFromContractWithCustomerBeforeOtherIncomeExcludingAssessedTax", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_hCOijSb9akCf77GpRIPuFQ", "name": "irmd:RevenueFromContractWithCustomerBeforeOtherIncomeExcludingAssessedTax", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://iradimed.com/role/DisclosureRevenueRecognitionContractLiabilitiesDetails", "longName": "99940203 - Disclosure - Revenue Recognition - Contract liabilities (Details)", "shortName": "Revenue Recognition - Contract liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "As_Of_9_30_2024_c7DkxU9n4kG1FWkteF2Frg", "name": "irmd:AdvancePaymentsFromCustomers", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_c7DkxU9n4kG1FWkteF2Frg", "name": "irmd:AdvancePaymentsFromCustomers", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://iradimed.com/role/DisclosureRevenueRecognitionCapitalizedContractCostsDetails", "longName": "99940204 - Disclosure - Revenue Recognition- Capitalized contract costs (Details)", "shortName": "Revenue Recognition- Capitalized contract costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "As_Of_9_30_2024_c7DkxU9n4kG1FWkteF2Frg", "name": "us-gaap:CapitalizedContractCostNet", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_c7DkxU9n4kG1FWkteF2Frg", "name": "us-gaap:CapitalizedContractCostNet", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails", "longName": "99940301 - Disclosure - Basic and diluted net income per share (Details)", "shortName": "Basic and diluted net income per share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "As_Of_9_30_2024_c7DkxU9n4kG1FWkteF2Frg", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_kXSTsTg9_kWRVGEUL0DbAw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_hCOijSb9akCf77GpRIPuFQ", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "Unit_Standard_shares_lK-kk8XvKUuIMIMIulGA9Q", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "unique": true } }, "R36": { "role": "http://iradimed.com/role/DisclosureInventoryNetDetails", "longName": "99940401 - Disclosure - Inventory, net (Details)", "shortName": "Inventory, net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "As_Of_9_30_2024_c7DkxU9n4kG1FWkteF2Frg", "name": "us-gaap:InventoryRawMaterials", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_c7DkxU9n4kG1FWkteF2Frg", "name": "us-gaap:InventoryRawMaterials", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://iradimed.com/role/DisclosurePropertyAndEquipmentNetDetails", "longName": "99940501 - Disclosure - Property and Equipment, net (Details)", "shortName": "Property and Equipment, net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "As_Of_9_30_2024_c7DkxU9n4kG1FWkteF2Frg", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_-LfaixwV5k2CcQpy-8NpAQ", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "unique": true } }, "R38": { "role": "http://iradimed.com/role/DisclosurePropertyAndEquipmentNetGeographicRegionDetails", "longName": "99940502 - Disclosure - Property and Equipment, net - geographic region (Details)", "shortName": "Property and Equipment, net - geographic region (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "As_Of_9_30_2024_c7DkxU9n4kG1FWkteF2Frg", "name": "us-gaap:PropertyPlantAndEquipmentNet", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_srt_StatementGeographicalAxis_country_US_HPq-9xM-8kuSdxp2oIteqA", "name": "us-gaap:PropertyPlantAndEquipmentNet", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "unique": true } }, "R39": { "role": "http://iradimed.com/role/DisclosureIntangibleAssetsNetDetails", "longName": "99940601 - Disclosure - Intangible Assets, net (Details)", "shortName": "Intangible Assets, net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "As_Of_9_30_2024_c7DkxU9n4kG1FWkteF2Frg", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_-LfaixwV5k2CcQpy-8NpAQ", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "unique": true } }, "R40": { "role": "http://iradimed.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails", "longName": "99940801 - Disclosure - Stock-Based Compensation - Stock-based compensation expense (Details)", "shortName": "Stock-Based Compensation - Stock-based compensation expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_hCOijSb9akCf77GpRIPuFQ", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_hCOijSb9akCf77GpRIPuFQ", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://iradimed.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "longName": "99940802 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details)", "shortName": "Stock-Based Compensation - Restricted Stock Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_vCd8dANQ9kar_D57-fc6fw", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_vCd8dANQ9kar_D57-fc6fw", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R42": { "role": "http://iradimed.com/role/DisclosureStockBasedCompensationPerformanceBasedRestrictedStockUnitsNarrativeDetails", "longName": "99940803 - Disclosure - Stock-Based Compensation - Performance-Based Restricted Stock Units - Narrative (Details)", "shortName": "Stock-Based Compensation - Performance-Based Restricted Stock Units - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_AwardTypeAxis_irmd_PerformanceBasedRestrictedStockUnitsMember_HgEDXV4UmUOiMcEXxWY2Pw", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_AwardTypeAxis_irmd_PerformanceBasedRestrictedStockUnitsMember_HgEDXV4UmUOiMcEXxWY2Pw", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R43": { "role": "http://iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails", "longName": "99940804 - Disclosure - Stock-Based Compensation - Stock Options and Restricted Stock Units Activity (Details)", "shortName": "Stock-Based Compensation - Stock Options and Restricted Stock Units Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_OKsNrFV8e0WnAGH3SRsBJg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_lK-kk8XvKUuIMIMIulGA9Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_OKsNrFV8e0WnAGH3SRsBJg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_lK-kk8XvKUuIMIMIulGA9Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R44": { "role": "http://iradimed.com/role/DisclosureIncomeTaxesDetails", "longName": "99940901 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_hCOijSb9akCf77GpRIPuFQ", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_hCOijSb9akCf77GpRIPuFQ", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "Unit_Standard_pure_WgZTFCKdcEeh9ULRDkb2fg", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "unique": true } }, "R45": { "role": "http://iradimed.com/role/DisclosureLeasesDetails", "longName": "99941001 - Disclosure - Leases (Details)", "shortName": "Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "irmd:OperatingLeaseRightOfUseAssetAndLiabilityAdjustment", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_dTT-8ywtTEyABf5-ti1nnw", "name": "us-gaap:LesseeOperatingLeaseExistenceOfResidualValueGuarantee", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "unique": true } }, "R46": { "role": "http://iradimed.com/role/DisclosureLeasesOperatingLeaseCostDetails", "longName": "99941002 - Disclosure - Leases - Operating lease cost (Details)", "shortName": "Leases - Operating lease cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_hCOijSb9akCf77GpRIPuFQ", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_hCOijSb9akCf77GpRIPuFQ", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R47": { "role": "http://iradimed.com/role/DisclosureLeasesMaturityOfOperatingLeaseLiabilityDetails", "longName": "99941003 - Disclosure - Leases - Maturity of operating lease liability (Details)", "shortName": "Leases - Maturity of operating lease liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "As_Of_9_30_2024_c7DkxU9n4kG1FWkteF2Frg", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_c7DkxU9n4kG1FWkteF2Frg", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R48": { "role": "http://iradimed.com/role/DisclosureCommitmentsAndContingenciesDetails", "longName": "99941101 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "As_Of_9_30_2024_c7DkxU9n4kG1FWkteF2Frg", "name": "us-gaap:PurchaseObligation", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_c7DkxU9n4kG1FWkteF2Frg", "name": "us-gaap:PurchaseObligation", "unitRef": "Unit_Standard_USD_YguWF-8oxki50JuNoNuJqg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } }, "R49": { "role": "http://iradimed.com/role/DisclosureSubsequentEventsDetails", "longName": "99941201 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "Duration_10_30_2024_To_10_30_2024_us-gaap_DividendsAxis_irmd_O2024Q2DividendsMember_psdvzHY_Yk-un4kUlhSu4Q", "name": "us-gaap:DividendsPayableDateDeclaredDayMonthAndYear", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_10_30_2024_To_10_30_2024_us-gaap_DividendsAxis_irmd_O2024Q2DividendsMember_psdvzHY_Yk-un4kUlhSu4Q", "name": "us-gaap:DividendsPayableDateDeclaredDayMonthAndYear", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "irmd-20240930x10q.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r24", "r511" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net of allowance for credit losses of $277,437 as of September 30, 2024, and $368,835 as of December 31, 2023", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r643" ] }, "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrual for Taxes Other than Income Taxes, Current", "terseLabel": "Other accrued taxes", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r26", "r484", "r669" ] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued Income Taxes, Current", "terseLabel": "Accrued income taxes", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": [ "r26", "r64" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://iradimed.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r17", "r85", "r383" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r573" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r34", "r511", "r710" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r409", "r632", "r633", "r634", "r635", "r670", "r711" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r586" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r586" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r586" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r586" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "verboseLabel": "Stock-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r19", "r20", "r216" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "auth_ref": [] }, "irmd_AdvancePaymentsFromCustomers": { "xbrltype": "monetaryItemType", "nsuri": "http://iradimed.com/20240930", "localname": "AdvancePaymentsFromCustomers", "crdr": "credit", "presentation": [ "http://iradimed.com/role/DisclosureRevenueRecognitionContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Advance Payments From Customers", "terseLabel": "Advance payments from customers" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r619" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r545", "r555", "r565", "r597" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r548", "r558", "r568", "r600" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r620" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r586" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r593" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r549", "r559", "r569", "r593", "r601", "r605", "r613" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r611" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://iradimed.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r246", "r251" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for credit losses", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r89", "r155", "r159" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "irmd_AmortizationOfExtendedWarrantyAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://iradimed.com/20240930", "localname": "AmortizationOfExtendedWarrantyAgreements", "crdr": "credit", "presentation": [ "http://iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of amortization of extended warranty agreements.", "label": "Amortization of Extended Warranty Agreements", "terseLabel": "Amortization of extended warranty agreements" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://iradimed.com/role/DisclosureIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense of intangible assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r3", "r167", "r173", "r495" ] }, "irmd_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://iradimed.com/20240930", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAbstract", "presentation": [ "http://iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "documentation": "N/A", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Abstract]", "terseLabel": "Anti-dilutive stock" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive stock options and restricted stock units", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r136" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r63", "r71", "r88", "r105", "r140", "r142", "r148", "r149", "r156", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r280", "r284", "r307", "r377", "r433", "r492", "r493", "r511", "r536", "r663", "r664", "r676" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r81", "r91", "r105", "r156", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r280", "r284", "r307", "r511", "r663", "r664", "r676" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r608" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r609" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r604" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r604" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r604" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r604" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r604" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r604" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://iradimed.com/role/DisclosureStockBasedCompensationPerformanceBasedRestrictedStockUnitsNarrativeDetails", "http://iradimed.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "http://iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r607" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r606" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r605" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r605" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://iradimed.com/role/DisclosureBasisOfPresentationPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_CapitalizedContractCostNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalizedContractCostNet", "crdr": "debit", "presentation": [ "http://iradimed.com/role/DisclosureRevenueRecognitionCapitalizedContractCostsDetails" ], "lang": { "en-us": { "role": { "label": "Capitalized Contract Cost, Net", "terseLabel": "Capitalized contract costs", "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer." } } }, "auth_ref": [ "r163" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r11", "r83", "r482" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r11", "r50", "r104" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase/decrease in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r50" ] }, "us-gaap_ChangeInContractWithCustomerLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInContractWithCustomerLiabilityAbstract", "presentation": [ "http://iradimed.com/role/DisclosureRevenueRecognitionContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Change in Contract with Customer, Liability [Abstract]", "terseLabel": "Changes in contract liabilities" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r584" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r581" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r579" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r585" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r585" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://iradimed.com/role/DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r59", "r184", "r185", "r468", "r657", "r658" ] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://iradimed.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock, Dividends, Per Share, Declared", "verboseLabel": "Cash dividend per share declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r60" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r526", "r527", "r528", "r530", "r531", "r532", "r533", "r632", "r633", "r635", "r670", "r709", "r711" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails", "http://iradimed.com/role/StatementCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r33" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r33", "r421" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r33" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r5", "r33", "r421", "r439", "r711", "r712" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Common stock; $0.0001 par value per share; 31,500,000 shares authorized; 12,669,912 shares issued and outstanding as of September 30, 2024, and 12,660,313 shares issued and outstanding as of December 31, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r33", "r379", "r511" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r590" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r589" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r591" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r588" ] }, "irmd_ComputerSoftwareAndHardwareMember": { "xbrltype": "domainItemType", "nsuri": "http://iradimed.com/20240930", "localname": "ComputerSoftwareAndHardwareMember", "presentation": [ "http://iradimed.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to collection of computer programs and related data that provide instructions to a computer and information about long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Software And Hardware [Member]", "terseLabel": "Computer software and hardware" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://iradimed.com/role/DisclosureBasisOfPresentationPolicies" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Certain Significant Risks and Uncertainties", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r22", "r73" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": [ "http://iradimed.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Construction in Progress [Member]", "terseLabel": "Construction in-process", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetAndLiabilityAbstract", "presentation": [ "http://iradimed.com/role/DisclosureRevenueRecognitionContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://iradimed.com/role/DisclosureRevenueRecognitionTables" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Schedule of contract liabilities and changes in the contract liabilities", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r665" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://iradimed.com/role/DisclosureRevenueRecognitionContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability", "periodEndLabel": "Contract liabilities, ending balance", "periodStartLabel": "Contract liabilities, beginning balance", "totalLabel": "Total", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r199", "r200", "r211" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r199", "r200", "r211" ] }, "irmd_ContractWithCustomerLiabilityDecreaseDueToRecognitionOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://iradimed.com/20240930", "localname": "ContractWithCustomerLiabilityDecreaseDueToRecognitionOfRevenue", "crdr": "debit", "presentation": [ "http://iradimed.com/role/DisclosureRevenueRecognitionContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of decrease in contract liabilities due to recognition of revenue.", "label": "Contract with Customer, Liability, Decrease Due to Recognition of Revenue", "negatedLabel": "Decreases due to recognition of revenue" } } }, "auth_ref": [] }, "irmd_ContractWithCustomerLiabilityIncreaseDueToCashReceivedFromCustomers": { "xbrltype": "monetaryItemType", "nsuri": "http://iradimed.com/20240930", "localname": "ContractWithCustomerLiabilityIncreaseDueToCashReceivedFromCustomers", "crdr": "credit", "presentation": [ "http://iradimed.com/role/DisclosureRevenueRecognitionContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in contract liabilities due to cash received from customers.", "label": "Contract with Customer, Liability, Increase Due to Cash Received from Customers", "terseLabel": "Increases due to cash received from customers" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred revenue, non-current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r199", "r200", "r211" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Cost of Revenue", "terseLabel": "Cost of revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r44", "r105", "r156", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r307", "r492", "r663" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": [ "http://iradimed.com/role/DisclosureLeasesOperatingLeaseCostDetails", "http://iradimed.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Cost of Sales [Member]", "terseLabel": "Cost of revenue", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [ "http://iradimed.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r109", "r110", "r196", "r197", "r333", "r337", "r376", "r485", "r487" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax asset, net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r254", "r255" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://iradimed.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation", "terseLabel": "Depreciation expense of property and equipment", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r3", "r16" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation & amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r3", "r140", "r145", "r149", "r492", "r493" ] }, "irmd_DevicesMember": { "xbrltype": "domainItemType", "nsuri": "http://iradimed.com/20240930", "localname": "DevicesMember", "presentation": [ "http://iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to devices of the entity.", "label": "Devices:" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://iradimed.com/role/DisclosureRevenueRecognitionInformationByGeographicRegionDetails", "http://iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue", "verboseLabel": "Contract Liabilities", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r210", "r496", "r497", "r498", "r499", "r500", "r501", "r502" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://iradimed.com/role/DisclosureRevenueRecognitionInformationByGeographicRegionDetails", "http://iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r210", "r496", "r497", "r498", "r499", "r500", "r501", "r502" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://iradimed.com/role/DisclosureRevenueRecognitionTables" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of disaggregation of revenue by geographic region and revenue type", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r666" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://iradimed.com/role/DisclosureStockBasedCompensation" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r214", "r219", "r247", "r248", "r250", "r503" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Stock-Based Compensation" } } }, "auth_ref": [] }, "us-gaap_DividendPayableDateToBePaidDayMonthAndYear": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendPayableDateToBePaidDayMonthAndYear", "presentation": [ "http://iradimed.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Dividends Payable, Date to be Paid", "terseLabel": "Dividends payable, payment date", "documentation": "Date the declared dividend will be paid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r13" ] }, "us-gaap_DividendsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsAxis", "presentation": [ "http://iradimed.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Dividends [Axis]", "documentation": "Information by distribution of earnings to shareholder. Includes, but is not limited to, distribution paid and declared." } } }, "auth_ref": [] }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Dividends, Common Stock, Cash", "negatedLabel": "Dividends paid", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } }, "auth_ref": [ "r60" ] }, "us-gaap_DividendsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsDomain", "presentation": [ "http://iradimed.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Dividends [Domain]", "documentation": "Distributions of earnings to shareholders including but not limited to cash, property or capital stock." } } }, "auth_ref": [] }, "irmd_DividendsPaidAmountPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://iradimed.com/20240930", "localname": "DividendsPaidAmountPerShare", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "documentation": "This information represents dividend paid per share in amount.", "label": "Dividends Paid Amount Per Share" } } }, "auth_ref": [] }, "us-gaap_DividendsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableCurrent", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets", "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Dividends Payable, Current", "terseLabel": "Dividend payable", "verboseLabel": "Dividends declared not yet paid", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r26" ] }, "us-gaap_DividendsPayableDateDeclaredDayMonthAndYear": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableDateDeclaredDayMonthAndYear", "presentation": [ "http://iradimed.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Dividends Payable, Date Declared", "terseLabel": "Dividends payable, date declared", "documentation": "Date the dividend to be paid was declared, in YYYY-MM-DD format." } } }, "auth_ref": [ "r13" ] }, "us-gaap_DividendsPayableDateOfRecordDayMonthAndYear": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsPayableDateOfRecordDayMonthAndYear", "presentation": [ "http://iradimed.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Dividends Payable, Date of Record", "terseLabel": "Dividends payable, record date", "documentation": "Date the holder must own the stock to be entitled to the dividend, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r540" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r572" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r583" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": [ "http://iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "label": "Basic and Diluted Net Income per Share", "terseLabel": "Basic and Diluted Net Income Per Share" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails", "http://iradimed.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Basic net income per share (in dollars per share)", "verboseLabel": "Basic (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r98", "r116", "r117", "r118", "r119", "r120", "r121", "r126", "r128", "r133", "r134", "r135", "r139", "r275", "r278", "r293", "r294", "r373", "r389", "r488" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Net income per share:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails", "http://iradimed.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net income per share (in dollars per share)", "verboseLabel": "Diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r98", "r116", "r117", "r118", "r119", "r120", "r121", "r128", "r133", "r134", "r135", "r139", "r275", "r278", "r293", "r294", "r373", "r389", "r488" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShare" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Basic and Diluted Net Income per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r125", "r136", "r137", "r138" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://iradimed.com/role/DisclosureIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective rate (as a percent)", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r257", "r504" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued payroll and benefits", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r26" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://iradimed.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Stock-Based Compensation", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://iradimed.com/role/DisclosureStockBasedCompensationPerformanceBasedRestrictedStockUnitsNarrativeDetails", "http://iradimed.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average period of unrecognized compensation cost expected to be recognized", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r249" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://iradimed.com/role/DisclosureStockBasedCompensationPerformanceBasedRestrictedStockUnitsNarrativeDetails", "http://iradimed.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost for unvested award", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r668" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock Options", "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r538" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r538" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r538" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r622" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r538" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r538" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r538" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r538" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r577" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r618" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r618" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r618" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r5", "r79", "r94", "r95", "r96", "r111", "r112", "r113", "r115", "r120", "r122", "r124", "r141", "r157", "r158", "r180", "r198", "r265", "r266", "r272", "r273", "r274", "r276", "r277", "r278", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r308", "r309", "r310", "r311", "r312", "r313", "r315", "r317", "r329", "r388", "r400", "r401", "r402", "r409", "r459" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r587" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r545", "r555", "r565", "r597" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r542", "r552", "r562", "r594" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r593" ] }, "us-gaap_ExtendedProductWarrantyAccrual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ExtendedProductWarrantyAccrual", "crdr": "credit", "presentation": [ "http://iradimed.com/role/DisclosureRevenueRecognitionContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Extended Product Warranty Accrual", "terseLabel": "Extended warranty agreements", "documentation": "Amount as of the balance sheet date of the aggregate extended product warranty liability. Does not include the ending balance for the standard product warranty liability." } } }, "auth_ref": [ "r661", "r662" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Measurements" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://iradimed.com/role/DisclosureFairValueMeasurements" ], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r296", "r298", "r299", "r300", "r302", "r303", "r304", "r305", "r306", "r372", "r507", "r509" ] }, "irmd_FerroMagneticDetectionSystemsMember": { "xbrltype": "domainItemType", "nsuri": "http://iradimed.com/20240930", "localname": "FerroMagneticDetectionSystemsMember", "presentation": [ "http://iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to ferro magnetic detection systems.", "label": "Ferro Magnetic Detection Systems [Member]", "terseLabel": "Ferro Magnetic Detection Systems" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://iradimed.com/role/DisclosureIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r86", "r164", "r172", "r495" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "presentation": [ "http://iradimed.com/role/DisclosureIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "terseLabel": "Thereafter", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r653", "r713" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://iradimed.com/role/DisclosureIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r174", "r479", "r495" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": [ "http://iradimed.com/role/DisclosureIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "Three months remaining ending December 31, 2024", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [ "r713" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [ "http://iradimed.com/role/DisclosureIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2028", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r174", "r479", "r495" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://iradimed.com/role/DisclosureIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2027", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r174", "r479", "r495" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://iradimed.com/role/DisclosureIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r174", "r479", "r495" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://iradimed.com/role/DisclosureIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r166", "r168", "r169", "r170", "r171", "r172", "r175", "r176", "r340", "r341", "r479" ] }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "presentation": [ "http://iradimed.com/role/DisclosureIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "terseLabel": "Expected annual amortization expense" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://iradimed.com/role/DisclosureIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Intangible Assets, gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r164", "r172", "r341", "r495" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://iradimed.com/role/DisclosureIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Intangible Assets, net", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r166", "r172", "r175", "r176", "r178", "r340", "r479", "r495" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://iradimed.com/role/DisclosureIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r166", "r168", "r169", "r170", "r171", "r172", "r175", "r176", "r479" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": [ "http://iradimed.com/role/DisclosureIntangibleAssetsNetDetails", "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangible assets, net", "totalLabel": "Total", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r340", "r652" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r549", "r559", "r569", "r601" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r549", "r559", "r569", "r601" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r549", "r559", "r569", "r601" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r549", "r559", "r569", "r601" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r549", "r559", "r569", "r601" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r582" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://iradimed.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedTerseLabel": "Loss on disposal of property and equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r3" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "terseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r46", "r443" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://iradimed.com/role/DisclosureLeasesOperatingLeaseCostDetails", "http://iradimed.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r46" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Intangible Assets, net" } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Gross Profit", "totalLabel": "Gross profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r42", "r44", "r70", "r105", "r156", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r307", "r490", "r492", "r637", "r639", "r640", "r641", "r642", "r663" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before provision for income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r43", "r66", "r70", "r374", "r385", "r490", "r492", "r637", "r639", "r640", "r641", "r642" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED STATEMENTS OF OPERATIONS" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://iradimed.com/role/DisclosureLeasesOperatingLeaseCostDetails", "http://iradimed.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r181", "r182", "r183", "r295", "r297", "r301", "r398", "r399", "r444", "r479", "r508", "r680" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://iradimed.com/role/DisclosureLeasesOperatingLeaseCostDetails", "http://iradimed.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r182", "r183", "r295", "r297", "r301", "r398", "r399", "r444", "r479", "r508", "r680" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://iradimed.com/role/DisclosureIncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r106", "r253", "r257", "r258", "r259", "r260", "r261", "r262", "r267", "r269", "r270", "r271", "r407", "r504" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://iradimed.com/role/DisclosureIncomeTaxesDetails", "http://iradimed.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "verboseLabel": "Provision for income tax expense", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r72", "r77", "r123", "r124", "r140", "r146", "r149", "r256", "r257", "r268", "r390", "r504" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for income taxes", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r12", "r103", "r263", "r264" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Prepaid income taxes", "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r338", "r630" ] }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Deferred Income Taxes", "negatedLabel": "Deferred income taxes, net", "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued payroll and benefits", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Current Liabilities", "terseLabel": "Other current liabilities", "documentation": "Amount of increase (decrease) in current liabilities classified as other." } } }, "auth_ref": [ "r630" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPropertyAndOtherTaxesPayable", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Property and Other Taxes Payable", "terseLabel": "Other accrued taxes", "documentation": "The increase (decrease) during the period in the amount of cash payments due to taxing authorities for non-income-related taxes." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "irmd_IncreaseDecreaseInWarrantyReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://iradimed.com/20240930", "localname": "IncreaseDecreaseInWarrantyReserve", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Represents the increase (decrease) during the period in the carrying amount (including both current and noncurrent portions of the accrual) of the liability pertaining to warranty reserve.", "label": "Increase Decrease in Warranty Reserve", "terseLabel": "Warranty reserve" } } }, "auth_ref": [] }, "irmd_IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceBasedRestrictedStockUnits": { "xbrltype": "sharesItemType", "nsuri": "http://iradimed.com/20240930", "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfPerformanceBasedRestrictedStockUnits", "presentation": [ "http://iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of performance based restricted stock units arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable To Dilutive Effect Of Performance Based Restricted Stock Units", "terseLabel": "Performance-based restricted stock units" } } }, "auth_ref": [] }, "irmd_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnits": { "xbrltype": "sharesItemType", "nsuri": "http://iradimed.com/20240930", "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedStockUnits", "presentation": [ "http://iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of restricted stock units arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Restricted Stock Units", "terseLabel": "Restricted stock units" } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "presentation": [ "http://iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Stock options", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r129", "r130", "r131", "r135", "r218" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r549", "r559", "r569", "r593", "r601", "r605", "r613" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r611" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r541", "r617" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r541", "r617" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r541", "r617" ] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://iradimed.com/role/DisclosureIntangibleAssetsNet" ], "lang": { "en-us": { "role": { "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets, net", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r165", "r177", "r179", "r478", "r479" ] }, "irmd_InternallyDevelopedSoftwareInProcessMember": { "xbrltype": "domainItemType", "nsuri": "http://iradimed.com/20240930", "localname": "InternallyDevelopedSoftwareInProcessMember", "presentation": [ "http://iradimed.com/role/DisclosureIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to exclusive legal right granted by the government to the owner of the internally developed software to exploit an invention or a process for a period of time specified by law, which are in process.", "label": "Internally Developed Software In Process [Member]", "terseLabel": "Internally developed software - in process" } } }, "auth_ref": [] }, "irmd_InternallyDevelopedSoftwareInUseMember": { "xbrltype": "domainItemType", "nsuri": "http://iradimed.com/20240930", "localname": "InternallyDevelopedSoftwareInUseMember", "presentation": [ "http://iradimed.com/role/DisclosureIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to exclusive legal right granted by the government to the owner of the internally developed to exploit an invention or a process for a period of time specified by law, which are in use.", "label": "Internally Developed Software In Use [Member]", "terseLabel": "Internally developed software - in use" } } }, "auth_ref": [] }, "irmd_InternationalMember": { "xbrltype": "domainItemType", "nsuri": "http://iradimed.com/20240930", "localname": "InternationalMember", "presentation": [ "http://iradimed.com/role/DisclosurePropertyAndEquipmentNetGeographicRegionDetails", "http://iradimed.com/role/DisclosureRevenueRecognitionInformationByGeographicRegionDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to International, a geographic region of the entity.", "label": "International [Member]", "terseLabel": "International" } } }, "auth_ref": [] }, "us-gaap_InventoryAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryAdjustments", "crdr": "credit", "presentation": [ "http://iradimed.com/role/DisclosureInventoryNetDetails" ], "lang": { "en-us": { "role": { "label": "Inventory Adjustments", "negatedLabel": "Allowance for excess and obsolete", "documentation": "Amount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods." } } }, "auth_ref": [ "r15", "r627" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory, net." } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://iradimed.com/role/DisclosureInventoryNet" ], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventory, net", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r161" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "presentation": [ "http://iradimed.com/role/DisclosureInventoryNetDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r624" ] }, "us-gaap_InventoryGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryGross", "crdr": "debit", "presentation": [ "http://iradimed.com/role/DisclosureInventoryNetDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, Gross", "totalLabel": "Inventory before allowance for excess and obsolete", "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r627" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": [ "http://iradimed.com/role/DisclosureInventoryNetDetails", "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Inventory, Net", "terseLabel": "Inventory, net", "totalLabel": "Total", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r90", "r483", "r511" ] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterials", "crdr": "debit", "presentation": [ "http://iradimed.com/role/DisclosureInventoryNetDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r626" ] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcess", "crdr": "debit", "presentation": [ "http://iradimed.com/role/DisclosureInventoryNetDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in process", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r625" ] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWriteDown", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Inventory Write-down", "terseLabel": "Provision for excess and obsolete inventory", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r162" ] }, "us-gaap_LandMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LandMember", "presentation": [ "http://iradimed.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Land [Member]", "terseLabel": "Land", "documentation": "Part of earth's surface not covered by water." } } }, "auth_ref": [ "r667" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://iradimed.com/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of operating lease cost", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r673" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://iradimed.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r58", "r327" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://iradimed.com/role/DisclosureLeasesDetails", "http://iradimed.com/role/DisclosureLeasesOperatingLeaseCostDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Leases", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r321", "r328" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://iradimed.com/role/DisclosureLeasesDetails", "http://iradimed.com/role/DisclosureLeasesOperatingLeaseCostDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r321", "r328" ] }, "irmd_LesseeLeasingArrangementsOperatingLeasesRenewalTermBeginningInTwoThousandNineteen": { "xbrltype": "durationItemType", "nsuri": "http://iradimed.com/20240930", "localname": "LesseeLeasingArrangementsOperatingLeasesRenewalTermBeginningInTwoThousandNineteen", "presentation": [ "http://iradimed.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the term of the lessee's leasing arrangement renewal beginning in 2019, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Lessee Leasing Arrangements Operating Leases Renewal Term Beginning in Two Thousand Nineteen", "terseLabel": "Renewal term of lease beginning in 2019" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseExistenceOfResidualValueGuarantee": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseExistenceOfResidualValueGuarantee", "presentation": [ "http://iradimed.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Existence of Residual Value Guarantee [true false]", "terseLabel": "Lessee, operating lease, existence of residual value guarantee", "documentation": "Indicates (true false) whether lessee provided residual value guarantee for operating lease." } } }, "auth_ref": [ "r322" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://iradimed.com/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Schedule of maturity of operating lease liability", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r674" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [ "http://iradimed.com/role/DisclosureLeasesMaturityOfOperatingLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r326" ] }, "irmd_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne": { "xbrltype": "monetaryItemType", "nsuri": "http://iradimed.com/20240930", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearOne", "crdr": "credit", "presentation": [ "http://iradimed.com/role/DisclosureLeasesMaturityOfOperatingLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after first fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year One", "terseLabel": "Thereafter" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": [ "http://iradimed.com/role/DisclosureLeasesMaturityOfOperatingLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Three months remaining ending December 31, 2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r674" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://iradimed.com/role/DisclosureLeasesMaturityOfOperatingLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r326" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://iradimed.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Non-cancelable operating lease term", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r672" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://iradimed.com/role/DisclosureLeases" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r316" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r9", "r25", "r26", "r27", "r28", "r29", "r30", "r31", "r105", "r156", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r281", "r284", "r285", "r307", "r420", "r489", "r536", "r663", "r676", "r677" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r38", "r65", "r381", "r511", "r631", "r644", "r671" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r27", "r82", "r105", "r156", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r281", "r284", "r285", "r307", "r511", "r663", "r676", "r677" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "presentation": [ "http://iradimed.com/role/DisclosurePropertyAndEquipmentNetTables" ], "lang": { "en-us": { "role": { "label": "Long-Lived Assets by Geographic Areas [Table Text Block]", "terseLabel": "Schedule of property and equipment, net, information by geographic region", "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets." } } }, "auth_ref": [ "r55" ] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": [ "http://iradimed.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual", "terseLabel": "Legal matters accrued", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": [ "r186", "r623" ] }, "irmd_MRICompatibleIVInfusionPumpsMember": { "xbrltype": "domainItemType", "nsuri": "http://iradimed.com/20240930", "localname": "MRICompatibleIVInfusionPumpsMember", "presentation": [ "http://iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to MRI compatible IV infusion pumps, a product of the entity.", "label": "MRI Compatible IV Infusion Pumps [Member]", "verboseLabel": "MRI Compatible Intravenous (\"IV\") Infusion Pump Systems" } } }, "auth_ref": [] }, "irmd_MRICompatiblePatientVitalSignsMonitoringSystemsMember": { "xbrltype": "domainItemType", "nsuri": "http://iradimed.com/20240930", "localname": "MRICompatiblePatientVitalSignsMonitoringSystemsMember", "presentation": [ "http://iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to MRI compatible IV infusion pumps, a product of the entity.", "label": "MRI Compatible Patient Vital Signs Monitoring Systems [Member]", "terseLabel": "MRI Compatible Patient Vital Signs Monitoring Systems" } } }, "auth_ref": [] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://iradimed.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Machinery and Equipment [Member]", "terseLabel": "Machinery and equipment", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r585" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r585" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r604" ] }, "irmd_MonthlyBaseRent": { "xbrltype": "monetaryItemType", "nsuri": "http://iradimed.com/20240930", "localname": "MonthlyBaseRent", "crdr": "credit", "presentation": [ "http://iradimed.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the monthly base rent amount during the term of the lease.", "label": "Monthly Base Rent", "terseLabel": "Monthly base rent" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r612" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r586" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r102" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r102" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r50", "r51", "r52" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails", "http://iradimed.com/role/StatementCondensedStatementsOfOperations", "http://iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r45", "r52", "r67", "r80", "r92", "r93", "r96", "r105", "r114", "r116", "r117", "r118", "r119", "r120", "r123", "r124", "r132", "r156", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r275", "r278", "r294", "r307", "r387", "r441", "r457", "r458", "r534", "r663" ] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r585" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r549", "r559", "r569", "r593", "r601" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r576" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r575" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r593" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r612" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r612" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "terseLabel": "Other income, net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r47" ] }, "irmd_NumberOfLeaseContractsEntered": { "xbrltype": "integerItemType", "nsuri": "http://iradimed.com/20240930", "localname": "NumberOfLeaseContractsEntered", "presentation": [ "http://iradimed.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of separate lease contracts entered.", "label": "Number of Lease Contracts Entered", "terseLabel": "Number of non-cancelable operating leases entered" } } }, "auth_ref": [] }, "irmd_NumberOfMaterialLeaseContracts": { "xbrltype": "integerItemType", "nsuri": "http://iradimed.com/20240930", "localname": "NumberOfMaterialLeaseContracts", "presentation": [ "http://iradimed.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of separate material lease contracts outstanding.", "label": "Number of material lease contracts", "terseLabel": "Number of material lease contracts outstanding" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": [ "http://iradimed.com/role/DisclosureBasisOfPresentationDetails" ], "lang": { "en-us": { "role": { "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r491", "r494", "r638" ] }, "irmd_O2024Q2DividendsMember": { "xbrltype": "domainItemType", "nsuri": "http://iradimed.com/20240930", "localname": "O2024Q2DividendsMember", "presentation": [ "http://iradimed.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Distributions of 2024 Q2 earnings to shareholders including but not limited to cash, property or capital stock.", "label": "O 2024 Q2 Dividends [Member]" } } }, "auth_ref": [] }, "irmd_OperatingAndShortTermLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://iradimed.com/20240930", "localname": "OperatingAndShortTermLeasePayments", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating and short-term lease.", "label": "Operating and Short-term Lease Payments", "terseLabel": "Operating and short-term lease payments recorded within cash flow provided by operating activities" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Income from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r70", "r490", "r637", "r639", "r640", "r641", "r642" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://iradimed.com/role/DisclosureLeasesOperatingLeaseCostDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r323", "r510" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://iradimed.com/role/DisclosureLeasesMaturityOfOperatingLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]", "terseLabel": "Operating leases" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://iradimed.com/role/DisclosureLeasesMaturityOfOperatingLeaseLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "verboseLabel": "Present value of lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r319" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r319" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, non-current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r319" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://iradimed.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "verboseLabel": "Operating lease paid", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r320", "r324" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r318" ] }, "irmd_OperatingLeaseRightOfUseAssetAndLiabilityAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://iradimed.com/20240930", "localname": "OperatingLeaseRightOfUseAssetAndLiabilityAdjustment", "crdr": "debit", "presentation": [ "http://iradimed.com/role/DisclosureLeasesDetails", "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of adjustment of carrying amount of right-of-use asset and liability from operating lease.", "label": "Operating Lease, Right-of-Use Asset and Liability, Adjustment", "terseLabel": "ROU asset and liability adjustment" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Basis of Presentation" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://iradimed.com/role/DisclosureBasisOfPresentation" ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "verboseLabel": "Basis of Presentation", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": [ "r23", "r53", "r54", "r62" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "terseLabel": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r87" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r26", "r511" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r585" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r547", "r557", "r567", "r599" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r550", "r560", "r570", "r602" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r550", "r560", "r570", "r602" ] }, "irmd_PatentsFullyAmortizedMember": { "xbrltype": "domainItemType", "nsuri": "http://iradimed.com/20240930", "localname": "PatentsFullyAmortizedMember", "presentation": [ "http://iradimed.com/role/DisclosureIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law, which are fully amortized.", "label": "Patents - Fully Amortized [Member]", "terseLabel": "Patents - fully amortized" } } }, "auth_ref": [] }, "irmd_PatentsInProcessMember": { "xbrltype": "domainItemType", "nsuri": "http://iradimed.com/20240930", "localname": "PatentsInProcessMember", "presentation": [ "http://iradimed.com/role/DisclosureIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law, which are in process.", "label": "Patents - In Process [Member]", "terseLabel": "Patents - in process" } } }, "auth_ref": [] }, "irmd_PatentsInUseMember": { "xbrltype": "domainItemType", "nsuri": "http://iradimed.com/20240930", "localname": "PatentsInUseMember", "presentation": [ "http://iradimed.com/role/DisclosureIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law, which are in use.", "label": "Patents - In Use [Member]", "terseLabel": "Patents - in use" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r574" ] }, "us-gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividends", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of Dividends", "negatedLabel": "Dividends paid", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth_ref": [ "r49" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedLabel": "Taxes paid related to the net share settlement of equity awards", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r100" ] }, "us-gaap_PaymentsToAcquireOtherProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireOtherProductiveAssets", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Other Productive Assets", "negatedLabel": "Capitalized intangible assets", "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other." } } }, "auth_ref": [ "r48" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r48" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r584" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r584" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r576" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r593" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r586" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r575" ] }, "irmd_PerformanceBasedRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://iradimed.com/20240930", "localname": "PerformanceBasedRestrictedStockUnitsMember", "presentation": [ "http://iradimed.com/role/DisclosureStockBasedCompensationPerformanceBasedRestrictedStockUnitsNarrativeDetails", "http://iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "This member is stands for Performance-Based Restricted Stock Units.", "label": "Performance-Based Restricted Stock Units (\"PSUs\")", "terseLabel": "Performance Based Restricted Stock Units" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r577" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r621" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r576" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r628" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercises of stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r1", "r8" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r150", "r339", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r480", "r496", "r520", "r521", "r522", "r524", "r525", "r659", "r660", "r666", "r679", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708" ] }, "us-gaap_ProductWarrantyAccrualClassifiedCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductWarrantyAccrualClassifiedCurrent", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Product Warranty Accrual, Current", "terseLabel": "Warranty reserve", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r26", "r661", "r662" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r150", "r339", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r480", "r496", "r520", "r521", "r522", "r524", "r525", "r659", "r660", "r666", "r679", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "verboseLabel": "Net income", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r80", "r92", "r93", "r101", "r105", "r114", "r120", "r123", "r124", "r156", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r275", "r278", "r279", "r282", "r283", "r294", "r307", "r374", "r386", "r408", "r441", "r457", "r458", "r505", "r506", "r535", "r629", "r663" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property and Equipment, net", "verboseLabel": "Property and Equipment, net" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://iradimed.com/role/DisclosureLeasesDetails", "http://iradimed.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r4", "r327" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://iradimed.com/role/DisclosurePropertyAndEquipmentNet" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, net", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r57", "r74", "r75", "r76" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [ "http://iradimed.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r58", "r84", "r384" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://iradimed.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://iradimed.com/role/DisclosurePropertyAndEquipmentNetGeographicRegionDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property and equipment, net", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r327" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [ "http://iradimed.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://iradimed.com/role/DisclosurePropertyAndEquipmentNetGeographicRegionDetails", "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Total", "verboseLabel": "Total property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r4", "r327", "r375", "r384", "r511" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://iradimed.com/role/DisclosurePropertyAndEquipmentNetTables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r4" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://iradimed.com/role/DisclosureLeasesDetails", "http://iradimed.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r58", "r327" ] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "verboseLabel": "Allowance for credit losses", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r99", "r160" ] }, "irmd_PurchaseCommitmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://iradimed.com/20240930", "localname": "PurchaseCommitmentAbstract", "presentation": [ "http://iradimed.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Purchase Commitment [Abstract]", "terseLabel": "Purchase commitments" } } }, "auth_ref": [] }, "us-gaap_PurchaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligation", "crdr": "credit", "presentation": [ "http://iradimed.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Purchase Obligation", "terseLabel": "Purchase commitments", "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r574" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r574" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r542", "r552", "r562", "r594" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://iradimed.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r154", "r213", "r330", "r331", "r378", "r382", "r415", "r416", "r417", "r418", "r419", "r438", "r440", "r462" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": [ "http://iradimed.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r107", "r108", "r330", "r331", "r332", "r333", "r378", "r382", "r415", "r416", "r417", "r418", "r419", "r438", "r440", "r462" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://iradimed.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r154", "r213", "r330", "r331", "r378", "r382", "r415", "r416", "r417", "r418", "r419", "r438", "r440", "r462", "r675" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://iradimed.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r109", "r110", "r196", "r197", "r333", "r337", "r376", "r486", "r487" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r252", "r479", "r492", "r678" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://iradimed.com/role/DisclosureLeasesOperatingLeaseCostDetails", "http://iradimed.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "terseLabel": "Research and development", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r543", "r553", "r563", "r595" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r544", "r554", "r564", "r596" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r551", "r561", "r571", "r603" ] }, "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings", "verboseLabel": "Net share settlement of restricted stock units (in shares)", "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation." } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://iradimed.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "http://iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings", "terseLabel": "Net share settlement of restricted stock units", "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r35", "r60", "r380", "r403", "r404", "r406", "r422", "r511" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r79", "r111", "r112", "r113", "r115", "r120", "r122", "r124", "r157", "r158", "r180", "r265", "r266", "r272", "r273", "r274", "r276", "r277", "r278", "r286", "r288", "r289", "r291", "r292", "r315", "r317", "r400", "r402", "r409", "r711" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue Recognition", "terseLabel": "Revenue Recognition" } } }, "auth_ref": [] }, "irmd_RevenueFromContractWithCustomerBeforeOtherIncomeExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://iradimed.com/20240930", "localname": "RevenueFromContractWithCustomerBeforeOtherIncomeExcludingAssessedTax", "crdr": "credit", "presentation": [ "http://iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of revenue excluding tax, earned from contracts with customers before other income.", "label": "Revenue from Contract with Customer Before Other Income, Excluding Assessed Tax", "terseLabel": "Total Devices revenue" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [ "http://iradimed.com/role/DisclosureRevenueRecognitionInformationByGeographicRegionDetails", "http://iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total revenue", "totalLabel": "Total revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r68", "r69", "r140", "r143", "r144", "r147", "r149", "r150", "r151", "r153", "r209", "r210", "r339" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://iradimed.com/role/DisclosureRevenueRecognition" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue Recognition", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r78", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r212" ] }, "irmd_RevenueFromDisposablesAndServices": { "xbrltype": "monetaryItemType", "nsuri": "http://iradimed.com/20240930", "localname": "RevenueFromDisposablesAndServices", "crdr": "credit", "presentation": [ "http://iradimed.com/role/DisclosureRevenueRecognitionInformationByTypeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of revenue earned from disposables and services.", "label": "Revenue from Disposables and Services", "terseLabel": "Disposables, services and other" } } }, "auth_ref": [] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenues", "terseLabel": "Revenue", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r68", "r69", "r97", "r105", "r140", "r143", "r144", "r147", "r149", "r150", "r151", "r153", "r156", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r307", "r374", "r492", "r663" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "ROU asset recognized in exchange for new lease obligation", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r325", "r510" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r612" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r612" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of stock options and restricted stock units excluded from the calculation of diluted net income per share", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r14" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of computation of basic and diluted net income per share of common stock", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r636" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://iradimed.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r18" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://iradimed.com/role/DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of stock-based compensation", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r18" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://iradimed.com/role/DisclosureIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": [ "r166", "r172", "r175", "r176", "r178", "r340", "r479", "r495" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://iradimed.com/role/DisclosureIntangibleAssetsNetTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Summary of the components of intangible asset balances", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r495", "r651" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://iradimed.com/role/DisclosureInventoryNetTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventory", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r10", "r39", "r40", "r41" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://iradimed.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://iradimed.com/role/DisclosurePropertyAndEquipmentNetGeographicRegionDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r4", "r327" ] }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "presentation": [ "http://iradimed.com/role/DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Activity [Table Text Block]", "terseLabel": "Schedule of stock-based compensation activity", "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value." } } }, "auth_ref": [ "r6", "r7", "r61" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://iradimed.com/role/DisclosureStockBasedCompensationPerformanceBasedRestrictedStockUnitsNarrativeDetails", "http://iradimed.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "http://iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r215", "r217", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://iradimed.com/role/DisclosureIntangibleAssetsNetTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of expected annual amortization expense related to intangible assets (excludes in process intangible assets)", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r495", "r653" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r537" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r539" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://iradimed.com/role/DisclosurePropertyAndEquipmentNetGeographicRegionDetails", "http://iradimed.com/role/DisclosureRevenueRecognitionInformationByGeographicRegionDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": [ "r151", "r152", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r411", "r412", "r413", "r463", "r464", "r465", "r466", "r467", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r481", "r497", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r523", "r528", "r666", "r679", "r681", "r682", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708" ] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpense", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense", "terseLabel": "Sales and marketing", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingAndMarketingExpenseMember", "presentation": [ "http://iradimed.com/role/DisclosureLeasesOperatingLeaseCostDetails", "http://iradimed.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense [Member]", "terseLabel": "Sales and marketing", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": [ "r46" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://iradimed.com/role/DisclosureStockBasedCompensationPerformanceBasedRestrictedStockUnitsNarrativeDetails", "http://iradimed.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "http://iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Stock-Based Compensation", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r215", "r217", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Awards canceled/ forfeited (in shares)", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r229" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Awards granted (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r227" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding end of period (in shares)", "periodStartLabel": "Outstanding beginning of period (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r223", "r224" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Stock Options", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://iradimed.com/role/DisclosureStockBasedCompensationPerformanceBasedRestrictedStockUnitsNarrativeDetails", "http://iradimed.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "http://iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Ending balances (in shares)", "periodStartLabel": "Beginning balances (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "irmd_ShipmentsInTransit": { "xbrltype": "monetaryItemType", "nsuri": "http://iradimed.com/20240930", "localname": "ShipmentsInTransit", "crdr": "credit", "presentation": [ "http://iradimed.com/role/DisclosureRevenueRecognitionContractLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to shipments in-transit.", "label": "Shipments in-Transit", "terseLabel": "Shipments in-transit" } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r5", "r33", "r36", "r37", "r79", "r94", "r95", "r96", "r111", "r112", "r113", "r115", "r120", "r122", "r124", "r141", "r157", "r158", "r180", "r198", "r265", "r266", "r272", "r273", "r274", "r276", "r277", "r278", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r308", "r309", "r310", "r311", "r312", "r313", "r315", "r317", "r329", "r388", "r400", "r401", "r402", "r409", "r459" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://iradimed.com/role/DisclosurePropertyAndEquipmentNetGeographicRegionDetails", "http://iradimed.com/role/DisclosureRevenueRecognitionInformationByGeographicRegionDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [ "r151", "r152", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r411", "r412", "r413", "r463", "r464", "r465", "r466", "r467", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r481", "r497", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r523", "r528", "r666", "r679", "r681", "r682", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "verboseLabel": "Statement", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r111", "r112", "r113", "r141", "r317", "r339", "r405", "r410", "r414", "r415", "r416", "r417", "r418", "r419", "r421", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r434", "r435", "r436", "r437", "r438", "r440", "r442", "r443", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r459", "r529" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED STATEMENTS OF CASH FLOWS" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED BALANCE SHEETS" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r111", "r112", "r113", "r141", "r154", "r317", "r339", "r405", "r410", "r414", "r415", "r416", "r417", "r418", "r419", "r421", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r434", "r435", "r436", "r437", "r438", "r440", "r442", "r443", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r459", "r529" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r546", "r556", "r566", "r598" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://iradimed.com/role/DisclosureStockBasedCompensationStockOptionsAndRestrictedStockUnitsActivityDetails", "http://iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Awards exercised/vested (in shares)", "verboseLabel": "Exercise of stock options (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r5", "r32", "r33", "r60", "r228" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r5", "r33", "r36", "r37", "r60" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets", "http://iradimed.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "periodEndLabel": "Ending balances", "periodStartLabel": "Beginning balances", "totalLabel": "Total stockholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r33", "r36", "r37", "r56", "r423", "r439", "r460", "r461", "r511", "r536", "r631", "r644", "r671", "r711" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://iradimed.com/role/StatementCondensedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [ "http://iradimed.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Events", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r314", "r335" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": [ "http://iradimed.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r314", "r335" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://iradimed.com/role/DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r334", "r336" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "auth_ref": [] }, "irmd_SusiLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://iradimed.com/20240930", "localname": "SusiLLCMember", "presentation": [ "http://iradimed.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents details pertaining the Susi, LLC.", "label": "Susi, LLC" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r592" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r584" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r591" ] }, "us-gaap_TrademarksMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TrademarksMember", "presentation": [ "http://iradimed.com/role/DisclosureIntangibleAssetsNetDetails" ], "lang": { "en-us": { "role": { "label": "Trademarks [Member]", "terseLabel": "Trademarks", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style." } } }, "auth_ref": [ "r21", "r495", "r645", "r646", "r647", "r648", "r649", "r650", "r652", "r654", "r655", "r656" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r611" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r613" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://iradimed.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r614" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r615" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r615" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r613" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r613" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r616" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r614" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [ "http://iradimed.com/role/DisclosurePropertyAndEquipmentNetGeographicRegionDetails", "http://iradimed.com/role/DisclosureRevenueRecognitionInformationByGeographicRegionDetails" ], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r610" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r580" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "presentation": [ "http://iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]", "terseLabel": "Effect of dilutive securities:" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails", "http://iradimed.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average shares outstanding - Diluted (in shares)", "verboseLabel": "Diluted (in shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r127", "r135" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://iradimed.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average shares outstanding:" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://iradimed.com/role/DisclosureBasicAndDilutedNetIncomePerShareDetails", "http://iradimed.com/role/StatementCondensedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average shares outstanding - Basic", "verboseLabel": "Basic (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r126", "r135" ] }, "irmd_WinterSpringsFloridaFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://iradimed.com/20240930", "localname": "WinterSpringsFloridaFacilityMember", "presentation": [ "http://iradimed.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the Winter Springs, Florida facility.", "label": "Winter Springs, Florida Facility" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r578" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "330", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/985-20/tableOfContent" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r481": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r482": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r485": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r486": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r487": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r488": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r489": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r490": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r491": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r492": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r493": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r494": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r495": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r496": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r497": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r498": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r499": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r500": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r501": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r502": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r503": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r505": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r506": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r507": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r508": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r509": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r510": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r511": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r512": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r513": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r514": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r515": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r516": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r518": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r519": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r520": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r522": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r523": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r524": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r525": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r526": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r528": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r533": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r534": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r535": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r536": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r537": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r538": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r541": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r542": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r543": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r544": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r545": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r546": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r547": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r548": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r549": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r550": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r551": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r552": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r553": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r554": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r555": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r556": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r557": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r558": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r559": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r560": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r561": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r562": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r563": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r564": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r565": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r566": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r567": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r568": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r569": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r570": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r571": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r572": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r574": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r575": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r576": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r577": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r578": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r579": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r580": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r581": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r582": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r583": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r584": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r585": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r586": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r587": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r588": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r590": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r591": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r592": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r593": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r594": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r595": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r596": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r597": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r598": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r599": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r600": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r601": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r602": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r603": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r604": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r605": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r606": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r607": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r608": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r609": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r610": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r611": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r612": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r613": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r614": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r615": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r616": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r617": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r618": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r619": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r620": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r621": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r622": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r623": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 68 0001558370-24-014056-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-014056-xbrl.zip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